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     Abstract 
Developmental exposure to bisphenol A (BPA), a ubiquitous endocrine disrupting 
chemical, is associated with organ dysfunction and diseases in adulthood. However, little 
is known about its effects on the adrenal glands. Therefore, this thesis addresses this 
important question using both in vivo and in vitro approaches. BPA at environmentally 
relevant doses was administrated via diet to pregnant mice from embryonic day 7.5 to 
birth, following which mice were switched to a standard chow. At two months 
postnatally, adrenal glands and blood samples were collected from adult mouse offspring 
for structural and functional analysis. I found that: (a) BPA increased adrenal gland 
weight as well as plasma corticosterone levels; (b) BPA did not alter plasma levels of 
ACTH; and (c) BPA stimulated expression of the two key steroidogenic factors, 
steroidogenic acute regulatory protein (StAR) and cyp11A1 in female but not male 
offspring. To determine the molecular mechanisms underlying the BPA-induced StAR 
expression, I used human fetal adrenal cortical H295A cells as an in vitro model system, 
and showed that BPA increased StAR protein expression likely through an estrogen 
receptor (ER)-mediated mechanism independent of StAR gene transcription, translation 
and protein half-life. I then investigated the molecular mechanisms underlying the BPA-
induced increase in adrenal gland weight using the same in vitro model system. I 
demonstrated that (a) BPA increased cell number and protein levels of the three universal 
markers of proliferation (proliferating cell nuclear antigen (PCNA), cyclin D1 and D2, as 
well as sonic hedgehog (shh) and its key transcriptional regulator Gli1; (b) cyclopamine, 
a shh pathway inhibitor, blocked these stimulatory effects of BPA on cell proliferation; 
(c) BPA increased the nuclear translocation of ERβ; and (d) the ERb-specific agonist 
DPN mimicked while the ERb antagonist PHTPP abrogated the stimulatory effects of 
BPA on cell proliferation, and prevented BPA-induced activation of the shh signaling. 
Taken together, these findings demonstrate that developmental exposure to BPA 
adversely affects adrenal gland development and steroidogenic function in adult mouse 
offspring. Furthermore, they reveal novel molecular signaling mechanisms of BPA 
actions in regulating adrenal steroidogenic function and adrenal cortical cell proliferation.  
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1 INTRODUCTION 
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1.1 Bisphenol A 
Bisphenol A (BPA) is a widely used endocrine disrupting chemical (EDC) that has 
become a source of major health concerns 1-3. With an estimated production of six billion 
tons per year, BPA ranks as one of the most highly produced chemicals 4. Initially, it was 
synthesized by Dr. A.P. Dianin in 1891 for use as a synthetic estrogen, however, the 
discovery of more potent estrogenic compounds resulted in its discontinuation 2. During 
the 1940s and 50s, BPA was identified as a potentially important component of plastics 
and began to be utilized in the manufacture of polymers, polyvinyl chloride plastics, and 
flame retardant tetrabromobisphenol-A 1-4. Currently, it is commonly found in 
polycarbonate plastics, such as plastic containers, baby bottles, plastic water bottles, etc.; 
and in epoxy resins, which are used as an internal coating on food and beverage cans 5. 
Additionally, BPA is present in medical and dental equipment, thermal paper, and 
cardboard and has been detected in soil, water and air samples 2-4,6-8. The BPA used in 
packaging contains an ester bond linking BPA monomers onto polymers, making it 
susceptible to hydrolysis, thus allowing migration of BPA from the packaging into the 
contents 8. BPA has been demonstrated to leach out of plastic containers and liners of 
cans into the food or beverage products, a process that is enhanced in acidic or high 
temperature environments 2-4,6-8. The most common route of exposure to BPA is through 
ingestion, but exposure through dermal routes and inhalation is also possible 5. BPA is 
ubiquitous in the environment and is detectable in the urine of 91% of Canadians 9. 
 
Several human epidemiological studies have demonstrated an association between 
exposure to BPA and adverse health outcomes that include infertility, reproductive 
complications, childhood obesity, childhood asthma, and altered neurological 
development in children and adults 10-12. Furthermore, animal studies have shown that 
developmental exposure to BPA results in a wide range of adverse health effects 
including reproductive, cardiovascular, immunological, metabolic, behavioral, and 
neurological disorders, as well as certain cancers in adult offspring, and that many of 
these effects are sex specific 2,6,13.  
 3 
1.1.1 Mechanism of Action 
BPA is considered an environmental estrogen and an EDC 2-4,6,7 with the ability to bind to 
both α and β estrogen receptor subtypes (ER), androgen receptors (AR), G-protein 
coupled estrogen receptors (GPER), estrogen related receptors γ (ERRγ) and 
glucocorticoid receptors (GR) 5,7. Recent evidence also indicates that BPA exposure 
results in adverse effects through pregnane X receptors 14, peroxisome proliferator-
activated receptors 15, thyroid hormone signaling 5,7,15, NF-kB signaling 16, ion signaling 
17, and induces pro-inflammatory cytokines and chemokines 18,19. Additionally, prenatal 
BPA exposure, even at low doses, has been shown to cause epigenetic alterations, 
including DNA methylation and histone modifications 20. BPA’s effects on these 
receptors and pathways are based on (1) the presence of the receptors, (2) the level of 
expression of these receptors, (3) the dose of BPA, and (4) the level of endogenous 
hormones that compete with BPA for binding to these receptors. 
1.1.1.1 Estrogen Receptor 
Of particular interest are the actions of BPA through the ERs, due to the structural 
similarities of BPA to estrogen and its previous use as a synthetic estrogen (Figure 1.1) 
15. There are two distinct ER subtypes, ERα and ERβ, which are specific to cell type, with 
ERα primarily expressed in reproductive and insulin-sensitive tissues 15. Upon estrogen 
binding to the ER, a conformational change occurs and ER translocates to the nucleus of 
the cell. In the nucleus, ER can either bind (1) directly to estrogen response elements 
(ERE) on promoters of ER target genes to induce gene expression or (2) to transcriptional 
coactivators, such as Sp1 and Ap1 to induce gene expression 15,21. 
 4 
 
Figure 1.1: Chemical structure of BPA and estradiol.2 
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BPA acts as an agonist for ERβ and has dual agonist or antagonist actions for ERα and 
has a higher binding affinity to ERβ than to ERα 22-24. Thus, the effects of BPA on ER are 
largely dependent on the cell type and ER subtype present 2. However, BPA has been 
classified as a weak estrogen based on its low binding affinity for ER compared to 
naturally-occurring 17β-estradiol (~10,000-fold lower) 2. This leads to the claim that 
BPA will not have a large impact on ER in the presence of endogenous estrogens. 
However, additive effects of BPA and estradiol together have been demonstrated 25. 
Additionally, the effects of BPA may be explained by the “spare receptor” hypothesis, 
which states how a maximal response may be achieved by low concentrations of a 
hormone (or EDC), before occupancy of receptors are saturated 22. In addition, BPA has 
been shown to have non-genomic actions that are distinct from its actions on classical 
ERs 22,26. ER localized to the plasma membrane is known to activate a variety of 
pathways depending on receptor and cell type, including the extracellular regulated 
kinase/mitogen-activated protein kinase (ERK/MAPK), p38/MAPK, and phosphatidyl-
inositol-3-kinase/protein kinase B (PI3K/AKT) pathways 15. Moreover, BPA has been 
demonstrated to activate these non-genomic pathways by acting through membrane ER 
15. 
1.1.1.2 GPER 
GPER (also known as GPR30) is a G-protein coupled intracellular membrane receptor 
that is activated by estrogen and responsible for rapid estrogen signaling 27. BPA has 
been shown to be a strong agonist of the GPER, having non-genomic effects similar to 
estrogen 5,28. BPA has a half maximal inhibitory concentration (IC50) of 630 nM for the 
GPER, which is 8-50× higher than for classic ERs 28. Additionally, BPA can displace 
over 50% of the [3H] E2 binding to the plasma membrane of cells transfected with GPER, 
demonstrating BPA’s ability to interfere with estrogen signaling 28. 
1.1.1.3 Androgen Receptor 
Since BPA also affects the male reproductive system, the results of BPA binding to the 
androgen receptor have been investigated. BPA acts as a moderate antagonist of the AR 
in numerous cell types 5,7,29,30. BPA has an inhibitory concentration (IC50) value of 
3.9×104 nM for the AR in MA-10 cells 29. Additonally, BPA has been shown to 
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competitively bind to the AR and reduce AR nuclear translocation, and therefore its 
activity 30.  
1.1.1.4 Estrogen Related Receptor γ 
ERRγ are a subfamily of orphan receptors similar to ERs that can bind to estrogen related 
response elements as well as EREs 15. BPA has been shown to be a potent ERRγ agonist 
5, with an IC50 value of 13.1 nM, similar to that of the well-known strong ERRγ agonist 
4-hydroxytamoxifen 31. Thus, BPA may adversely affect signaling pathways through 
ERRγ binding 15. Moreover, there is potential for interaction or interference between 
ERRs and ERs during both the developmental period and adulthood 15. 
1.1.1.5 Glucocorticoid Receptor 
Since BPA has been demonstrated to act as both a GR agonist and antagonist 5,29,32,33, the 
actions of BPA on the GR may be tissue and dose specific. The affinity of BPA to the GR 
is relatively low, with an IC50 value of 6.7×104 nM in MA-10 cells and has antagonistic 
activity toward the GR 29. In the adipose cell line 3T3-L1, BPA displayed agonistic 
activity through the GR, which was also demonstrated in an in silico study 32,33. 
Additional evidence from our lab has demonstrated that BPA interferes with the 
glucocorticoid signaling pathway, resulting in inhibition of glucocorticoid target genes in 
A549 lung cells 16. 
1.1.1.6 Epigentic Modifications 
Recent evidence has emerged, supporting a potential for environmental chemicals to alter 
the epigenome during the period of embryogenesis. BPA has been demonstrated to 
induce numerous epigenetic alterations in rodent studies, including DNA methylation and 
histone modifications 5,34,35. For example, DNA methylation alterations have been 
observed to result in a shift in coat color after prenatal BPA exposure in viable yellow 
agouti mice 34. Moreover, oocyte maturation in porcine subjects was disrupted by BPA as 
a result of DNA methylation and histone modifications 35. 
1.1.2 Dose Response and Low Dose Effects 
Regulatory agencies typically establish the lowest observable adverse effect level 
(LOAEL) and/or no observed adverse effect level (NOAEL) for chemicals such as BPA 
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36. This enables the calculation of a reference dose that is considered safe for human 
exposure, based on the theory that “the dose makes the poison,” which stipulates that 
high doses of a chemical result in a larger physiological effect or in an increase in 
potential adverse effects 36. This theory is challenged by the testing of EDCs 36. In 
contrast to traditional monotonic response curves, many EDCs including BPA, have non-
monotonic dose response curves (NMDRCs). Traditional monotonic response curves can 
be either linear or non-linear, but the slope of the curve always remains in the same 
direction 36. NMDRCs are U-shaped or inverted U-shaped, such that the direction or 
slope of the curve changes over the range of doses being examined 36. Thus, outcomes of 
low-dose exposure to BPA cannot be inferred from results of higher dose exposures 37, 
making the traditional development method of LOAEL and NOAEL for BPA 
problematic. Since all doses of BPA tested had adverse effects, negating the possibility of 
determining a NOAEL value, the reference dose for human exposure of BPA was 
calculated using the LOAEL 36. Thus, the widespread use of BPA and consequent 
ubiquitous exposure to BPA even at very low doses is of concern. 
1.1.3 Pharmacokinetics 
The metabolism of BPA in humans, rodents, and primates is similar and is thought to 
occur through comparable mechanisms 38. Pharmacokinetic studies of BPA indicate that 
large amounts of BPA are subject to first pass metabolism in the liver, where it is 
conjugated into either the main metabolite, BPA-glucuronide (BPA-G), by uridine 5ʹ-
diphospho-glucuronosyltransferase (UGT) or BPA-sulfate (BPA-S) by sulfotransferase 
(SULT). Among UGTs, UGT2B15 shows the highest activity for conjugating BPA into 
BPA-G in human liver microsomes 39. In both rodents and humans, glucuronidation and 
sulfation produce inactive hydrophilic BPA metabolites that is excreted in the feces 38,40. 
However, unconjugated BPA is cleared by the kidneys and eliminated in the urine of 
primates, but is excreted primarily in the feces of rodents 38. This difference in route of 
elimination raises the question of potential differences in metabolism and circulating 
levels of BPA. Taylor, et al. 38  demonstrated that oral administration of BPA results in 
similar levels of unconjugated BPA in the circulation and identical rates of clearance in 
non-human primates and rodents. However, in pregnant rhesus monkeys, the systemic 
bioavailability or the percent of unconjugated BPA that reaches the systemic circulation 
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of BPA is considerably lower; only 0.48% 41. Rapid conjugation of BPA was 
demonstrated when pregnant rhesus monkeys were injected with 100 µg/kg bodyweight 
(bw) of unconjugated BPA, and at the five-minute initial sampling point, 87% of the BPA 
detected was in the conjugated form. The presence of unconjugated BPA in the blood 
demonstrates either (1) incomplete first pass metabolism, (2) a bypass of first pass 
metabolism or (3) the potential for deconjugation of BPA metabolites into unconjugated 
BPA 4. Indeed, evidence suggests that in the intestine and colon, conjugated BPA can be 
deconjugated back into active BPA in rodents 4. Clearly, additional investigation is 
required to determine the pharmacokinetics of BPA and the potential differences in 
experimental animal models versus human exposure to comprehend the risks of BPA 
exposure. 
During pregnancy, the placenta plays a critical role in controlling potential toxins that can 
reach the fetal circulation (Figure 1.2). Detectable levels of BPA were present in the 
placentae of rhesus monkeys given a single injection of 100 µg/kg bw BPA 41 and of that, 
29% was unconjugated BPA 41. Using a placental transfer model, 27% of unconjugated 
BPA was shown to cross from the maternal circulation of the placenta to the fetal 
circulation, indicating that unconjugated BPA can freely cross the placenta 42. Moreover, 
this model demonstrated that the placenta plays no role in conjugating active BPA into 
BPA-G, since BPA-G was detected in neither the maternal nor the fetal placental 
circulation 42. In addition to passive diffusion of BPA, there are active placenta transport 
proteins such as organic anion transporting polypeptide (Oatp) and multidrug resistance 
associated protein (Mrp) transporter family members that aid in the transport of 
conjugated BPA 40,43,44. BPA-G has been shown to cross into the placenta via the 
Oatp4a1 transport and then into fetal circulation by Mrp1 transporter 40,44. Thus, BPA has 
the potential to reach fetal circulation in both conjugated and active forms. 
The fetal liver is reported to have a 36-fold lower level of UGT2B15 than the adult liver, 
suggesting that the fetus has a decreased potential to metabolize BPA 40,45,46. While BPA-
G is considered to be inactive, β-glucuronidase in the fetal liver can deconjugate BPA 
into the active form 40,47. Thus, the risk of BPA to the fetus is compounded by its ability 
to de-conjugate BPA-G, as well as by its undeveloped drug detoxifying system 40,46. 
Additionally, since BPA-G is water soluble and cannot cross back through the placenta 
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into maternal circulation after excretion in the fetal urine, it may become trapped in the 
amniotic fluid where it has the potential to continually re-enter fetal circulation 47. Thus, 
there is growing concern about the risk of the developing fetus to prenatal exposure to 
BPA. 
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Figure 1.2: Prenatal pharmacokinetics of BPA 
Absorption of BPA occurs in the maternal intestines, BPA can either (1) be metabolized 
by the maternal liver to BPA-G, by UGTs, and then transported across the placenta by 
transport proteins or (2) freely diffuse across the placenta unconjugated and reach the 
fetal circulation. Conjugated BPA in the fetus can be unconjugated by b-Gase by the fetal 
liver to unconjugated BPA. Unconjugated BPA can then reach target fetal organs and 
accumulate in the fetus. Abbreviations: BPA, Bisphenol A; UGT, uridine 5’-diphospho-
glucuronosyltransferase; BPA-G, BPA-glucuronide; b-Gase, β-glucuronidase. 
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1.1.4 Human Exposure to BPA 
It is estimated that 90-95% of people have detectable levels of BPA in their urine, 
demonstrating the universality of BPA exposure 9,15. Ninety percent of BPA exposure is 
thought to result through food and drink exposure, with the remaining exposure through 
dust, dental products and surgery, and dermal contact 15. Health Canada has designated 
the level of tolerable daily intake (TDI) of BPA to be 25 µg/kg bw per day for the 
average Canadian adult, and in 2010 banned the use of BPA in baby bottles and food 
containers 48,49. Even with such regulations in place, estimated BPA daily intake levels in 
Canadian infants are reported as 0.22-0.33 µg/kg bw/day and levels in adults have been 
estimated at 0.052-0.081 µg/kg bw/day 50. In the United States, the Food and Drug 
Administration (FDA), eliminated the use of BPA in epoxy resins of baby food 
containers due to marketplace demands in 2013 49. However, the FDA continues to state 
that BPA is safe for consumers at their current levels 49. Similarly, the European Food 
and Safety Authority (EFSA) reported there was no health concern of dietary BPA for 
any age group 49, but as a precautionary measure, reduced the levels of safe BPA 
exposure from 50 µg/kg bw/day to 4 µg/kg bw/day, and banned the sale of baby bottles 
containing BPA 49. Nonetheless, government agency regulations aimed at preventing 
exposure to BPA in infants and young children do not address the issue of fetal exposure 
to BPA during pregnancy via maternal sources, which has been shown to have 
permanent, long lasting effects on human health 11,12. 
1.1.4.1 Developmental Origins of Health and Disease 
Over thirty years ago, David Barker first considered the possibility that poor maternal 
malnutrition resulting in low birth weight of the fetus led to premature death due to 
metabolic and cardiovascular complications later in life for the offspring 51. This concept 
was expanded to include early life exposure to environmental toxins that can lead to 
subtle changes during development that lead to dysfunction and/or diseases later in life 
and is now referred to as the Developmental Origins of Health and Disease (DOHaD) 
hypothesis 51. Application of this hypothesis to BPA implies that prenatal exposure to 
BPA can have long lasting effects that span a lifetime due to alterations in gene and 
protein expression that occur during the critical period of organ development 51,52. 
Epigenetic alterations in the fetus are also thought to play an important role in the 
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susceptibility to dysfunction and/or disease later in life 52. Furthermore, many of these 
developmental effects can be sex-specific and are often irreversible 51. As such, 
developmental exposure to environmental stressors (altered nutritional status, 
environmental chemical, stress, etc.) can have lasting effects on the offspring, which is 
not yet fully understood. 
1.1.4.2 BPA during Pregnancy  
Dynamic changes occur in drug metabolism and transport during pregnancy, and thus 
BPA metabolism may vary in pregnant versus non-pregnant populations 40,53. During 
pregnancy, women have increased plasma volume and clearance as well as altered 
metabolism depending on the specific enzymes involved 40,53. Consequently, there is a 
possibility of an increased half-life of BPA in the maternal circulation thereby increasing 
potential fetal exposure 47. 
 
While the placenta is considered a protective barrier between the mother and fetus, many 
environmental chemicals pass through the placenta due to their high lipophilic properties 
54. Furthermore, the presence of both ERα and ERβ on the placenta make it vulnerable to 
estrogenic environmental contaminants such as BPA 54. The ban of BPA from baby 
products (e.g. baby bottles and toys) does not reduce the risk of BPA exposure to the 
developing fetus 11,12. Indeed, pregnant German women were found to have plasma levels 
of BPA as high as 9.2 ng/mL, and their fetuses had plasma levels of BPA averaging 12.7 
ng/mL, proving that BPA crosses the placenta 55. This finding was supported by North 
American and Canadian studies that determined BPA levels in maternal serum to be 
between 0.5-22.3 ng/mL 56, and BPA levels in urine from pregnant women to be between 
0.16-43.20 ng/mL, respectively 57. BPA has also been detected in cord blood, amniotic 
fluid, and breast milk 55,58-60. Taken together, these studies show cause for concern about 
in utero exposure to BPA during fetal development 13. 
1.1.4.3 Fetal Exposure to BPA 
One of the major functions of the placenta is to act as a barrier preventing xenobiotics in 
the maternal circulation from reaching the fetus 42. However, the placenta appears to be 
ineffective at preventing the transfer of BPA, since unconjugated BPA readily crosses the 
placenta by passive diffusion in both directions 42,61. While members of the BPA 
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metabolizing enzyme UGT and SULT families are expressed in the placenta, they have 
negligible efficacy in conjugating BPA in this milieu 42. In addition to its detection in 
cord blood, fetal blood, placental tissues, and amniotic fluid 3,42,55, BPA was found in 
fetal tissues, including fetal liver samples (9.02 ng/g unconjugated BPA, 25.8 ng/g total 
BPA) collected from the greater Montreal area between 1998 and 2008 62. Thus, BPA is 
readily crossing the placental barrier and reaching the fetus. 
Various animal models employed to examine the effects of fetal exposure to BPA have 
demonstrated that fetal BPA exposure has a wide range of adverse effects including 
reproductive, cardiovascular, immunological, metabolic, behavioral, and neurological 
disorders; contributes to the development of certain cancers in adult offspring; and that 
many of these effects are sex-specific 2,6,13. In mouse models, pre- and post-natal 
exposure to low doses of BPA affected the organization of the central nervous system and 
neurotransmitter receptor systems, resulting in reduced and/or reversed sexual differences 
in the emotional behavior of offspring 63,64. Moreover, in this model, low doses, but not 
high doses of BPA, resulted in metabolic disruption (increased body weight, adipocyte 
number, abdominal fat, insulin levels, and impaired glucose tolerance) in male offspring 
63,65. Our laboratory has demonstrated that prenatal exposure to BPA impairs the 
development of the fetal liver 66, pancreas 67 and lungs 68. Therefore, due to the 
ubiquitous nature of BPA, there is increasing concern for the potential long-term 
consequences of developmental exposure to BPA.   
1.2 The Adrenal Gland 
The adrenal glands are an important endocrine organ that synthesizes hormones in its 
cortex and medulla 69,70. The adrenal cortex produces steroid hormones during fetal and 
adult life, including glucocorticoids, aldosterone, progesterone, and precursors of 
testosterone and estradiol 69,70. These hormones are produced via the steroidogenic 
pathway, which starts with cholesterol and involves a number of cytochrome P450 
enzymes and hydroxysteroid dehydrogenases 69,70. 
The adult adrenal cortex is divided into three zones: the zona glomerulosa (ZG), zona 
fasciculata (ZF) and the zona reticularis (ZR) 70 (Table 1.1). The outermost adrenal zone, 
the ZG, secretes aldosterone and is a key component of the renin-angiotensin-aldosterone 
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axis, which is responsible for the regulation of water balance 71,72. Aldosterone 
transcriptionally regulates a number of proteins and enzymes involved in maintaining 
water and sodium balance, and potassium excretion in the kidney 71,72. Cells of the ZG 
contain numerous mitochondria, and some cytoplasmic lipid droplets 71. The middle 
adrenal cortex zone, the ZF, secretes glucocorticoids, a key hormone in the 
hypothalamic-pituitary-adrenal (HPA) axis 71. Cells in the ZF are arranged in bundles, 
called fascicles that are surrounded by numerous capillaries 71. These cells contain large 
numbers of mitochondria, as well as prominent smooth endoplasmic reticulum and large 
lipid droplets used for steroidogenesis 71. The ZR, the innermost adrenal cortex zone, 
secretes dehydroepiandrosterone (DHEA), a precursor of testosterone and estrogens 71. 
Cells of the ZR are similar in shape and size to the ZF but have more lysosomes and 
fewer lipid droplets 71. The adrenal medulla is composed of chromaffin cells that 
synthesize epinephrine and norepinephrine 73. All adrenal gland hormones play various 
critical roles in maintaining homeostasis. However, this thesis specifically focuses on the 
regulation of adrenal glucocorticoid synthesis.  
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Table 1.1: Hormone production in the adrenal cortex. 
 Zona Glomerulosa Zona Fasciculata Zona Reticularis 
Stimulus Angiotensin II  ACTH ACTH 
Primary 
Receptor 
Angiotensin II 
receptor MC2R MC2R 
Hormone 
Product 
Mineralocorticoids 
(Aldosterone) 
Glucocorticoid 
(cortisol/corticosterone) 
Androgens 
(DHEA) 
Function Regulation of intravascular volume 
Glucose homeostasis 
Stress response 
Immune response 
Adrenarche 
 
Abbreviations: ACTH, Adrenocorticotropic hormone; MC2R, melanocortin 2 receptor; DHEA, 
dehydroepiandrosterone. 
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1.2.1 The HPA Axis 
The production of glucocorticoids is regulated by the HPA axis (Figure 1.3) 74,75. Upon 
stimulation, corticotrophin releasing hormone (CRH) is synthesized and secreted from 
the paraventricular nucleus in the hypothalamus into the hypophyseal portal vessels to be 
transported to the anterior pituitary gland 75. Binding of CRH to the CRH receptor 1 
(CRHR1) in the anterior pituitary gland induces synthesis of adrenocorticotrophic 
hormone (ACTH) from the prohormone proopiomelanocortin (POMC) 75. ACTH is 
released into the systemic circulation where it binds melanocortin 2 receptor (MC2R), a 
G-protein coupled receptor expressed on the adrenal cortex, to stimulate steroidogenesis 
76. The stimulatory effect of ACTH can increase steroidogenesis in a number of ways 
including (1) promoting adrenal cortex growth over the long term 77; (2) promoting the 
up- regulation of its receptor MC2R 78; (3) increasing the presence of the scavenger 
receptor class B member 1 (SRB1) and low-density lipoprotein (LDL) receptors, thereby 
enabling enhanced uptake of cholesterol 78; and (4) up-regulating key steroidogenic 
enzymes such as cyp11A1 77,78 and steroidogenic acute regulatory protein (StAR) 78.  
The HPA axis is tightly regulated by a glucocorticoid negative feedback mechanism 75. 
Glucocorticoids produced from the adrenal gland provide a negative feedback signal to 
the hypothalamus and pituitary gland to inhibit further glucocorticoid production through 
altering transcription of HPA components upon binding to glucocorticoid responsive 
elements (GREs) or interaction with various transcription factors 75. Disruptions in the 
development and formation of the HPA axis pathways during the critical window of fetal 
development has long lasting health consequences that extend into adulthood, including 
metabolic syndrome 79 and anxiety/mood disorders 80,81. 
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Figure 1.3: Hypothalamic-pituitary-adrenal (HPA) axis.  
Hypothalamus releases CRH binding to CRHR-1 receptors on the anterior pituitary gland. 
Binding of CRH stimulates the release of ACTH which binds to MC2Rs on the adrenal cortex, 
causing the release of glucocorticoids; cortisol in humans and corticosterone in mice. 
Glucocorticoids will negatively feedback to both the hypothalamus and anterior pituitary gland to 
regulate its expression. Abbreviations: CRH, corticotrophin releasing hormone; CRHR-1, 
corticotrophin releasing hormone receptor-1; ACTH, adrenocorticotrophic hormone; MC2R, 
melanocortin 2 receptor.  
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1.2.2 Physiological Function 
Glucocorticoids are essential in maintaining whole body homeostasis through their 
various actions in numerous tissues. Glucocorticoids play a major role in glucose 
metabolism in stressful environments through increasing serum glucose and amino acids 
by (1) increasing catabolism of muscle to increase circulating amino acids; (2) increasing 
amino acid uptake in the liver to increase gluconeogenesis and glycogenesis; and (3) 
decreasing peripheral glucose uptake in muscle and adipose tissue 78,79,82,83.  Additionally, 
glucocorticoids increase general catabolism by increasing lipid hydrolysis and increasing 
fatty acids and by increasing bone and connective tissue catabolism, which may result in 
osteopenia, and thinning of skin and support structures 78,79,82-84. Glucocorticoids also 
play an important role in the immune system by suppressing the inflammatory response 
while promoting anti-inflammatory actions 78,85. 
1.2.2.1 Cushing’s Disease 
Cushing’s disease (CD) is an endocrine disorder characterized by the overproduction of 
ACTH due to a pituitary tumor, commonly an adenoma, which results in overstimulation 
of the adrenal gland 86-89. While CD is the most common form of Cushing’s syndrome, 
other causes include excessive use of glucocorticoids 86-89. Cushing’s syndrome is defined 
by increased cortisol in both the serum and urine, with a disruption of the HPA axis and 
cortisol circadian rhythm 86. The prevalence of CD is reported as 40 cases per million, 
and has highest prevalence in women aged 40-60 years old 86. Symptoms of excessive 
glucocorticoids include increased weight gain, fatigue, insulin resistance, skin thinning, 
and bruising 86,87,89. The wide range of comorbidities associated with CD includes 
hypertension, diabetes mellitus, dyslipidemia, osteoporosis, depression, impaired sexual 
function in men, menstrual disorders in women, and infertility in both men and women 
86,88. Additionally, patients with persistent or recurring CD or excessive glucocorticoid 
production have increased risk of mortality 86. Untreated CD has a five-year survival rate 
of less than 50% 89; with the most common causes of mortality being cardiovascular 
disease and infection 86,87. Patients with CD report a significant decrease in their quality 
of life, physically, mentally, and emotionally 86-88. Treatment for CD varies, depending 
on the source of the condition, but the first line of treatment is surgery (pituitary and/or 
adrenal gland) 86,87. Pharmacological therapies, including steroidogenesis inhibitors (e.g. 
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ketoconazole, metyrapone, etomidate) and glucocorticoid receptor antagonists (e.g. 
mifepristone) are used preoperatively or for reoccurrences 87. Treatment of CD may 
reduce symptoms of the disease, but comorbidities may be irreversible, therefore 
potential risk persists throughout life 88. 
1.2.2.2 Addison’s disease  
Opposite to adrenal over-activity is adrenal insufficiency, often known as Addison’s 
disease, which is a rare chronic endocrine disease that results in loss of adrenal function, 
with a subsequent decrease in adrenal production of glucocorticoids, as well as 
mineralocorticoids in certain cases 90-92. Adrenal insufficiency is classified as primary or 
secondary adrenal insufficiency 90,91. Primary insufficiency, which affects 0.01% of the 
population, results from direct inhibition of glucocorticoid production from the adrenal 
gland. Primary adrenal insufficiency can be caused by autoimmune adrenalitis, infectious 
adrenalitis (e.g. AIDS, tuberculous adrenalitis), bilateral adrenal hemorrhage, adrenal 
infiltration, adrenalectomy, drug-induced adrenal insufficiency, or various genetic 
disorders (mutations in any of the adrenal steroidogenic enzymes, regulatory transcription 
factors, or receptors) 90,91. Secondary adrenal insufficiency has a prevalence of 1 in 5,000 
and is a result of decreased stimulation of adrenal gland steroidogenesis due to decreased 
ACTH levels 90,91. This can be a result of tumors of the pituitary gland or hypothalamus, 
chronic glucocorticoid use, head trauma, isolated congenital ACTH deficiency, 
proopiomelanocortin-deficiency, or combined pituitary-hormone deficiency 90,91. Adrenal 
insufficiency presents with a range of symptoms depending on whether the adrenal 
insufficiency involves decreased glucocorticoids, mineralocorticoids, and/or androgens 92. 
Common clinical manifestations of both primary and secondary adrenal insufficiency 
include fatigue, anorexia, muscle weakness, weight loss, light-headedness, nausea, 
vomiting, headache, sweating, salt craving, and, in women, dry itchy skin and loss of 
libido 90-92. In addition, adrenal insufficiency can result in an adrenal crisis 90,92, which is a 
severe lack of glucocorticoids during extreme stress, infection, or trauma, and can be life 
threatening 90. Monitoring of glucocorticoid levels and adjustment during times of stress 
can prevent adrenal crisis, but mortality rates are still 1.5-2 fold higher in patients 
suffering from adrenal insufficiency 90. Current treatment of adrenal insufficiency is to 
compensate for the glucocorticoid and mineralocorticoids deficiency (only in primary 
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adrenal insufficiency), with multiple daily tablets of hydrocortisone or prednisone and 
fludrocortisone in doses that mimic normal hormone secretion patterns 91,92. Primary 
adrenal insufficiency results in a decrease in lifespan of 3.2 years in women and 11.2 
years in men, compared to the general population, mainly due to increased acute adrenal 
failure, infections, and sudden death 92. People suffering from adrenal insufficiency report 
a decreased perception of health status and quality of life 92. 
1.2.2.3 Adrenocortical Cancer 
Adrenal cortical tumors (ACTs) are classified as either malignant adrenal cortical 
carcinomas (ACCs) or benign adrenal adenomas (ACA) 93,94. Small ACA’s are relatively 
common, affecting about 3-10% of the population 94. In contrast, ACCs are a rare form of 
cancer with an annual incidence rate of between 1 to 2 million 93,94. These tumors present 
with an aggressive phenotype and the patients have a poor prognosis 94,95. They are 
characterized by altered production of steroid hormones, uncontrolled tumor growth and 
metastases to other tissues 95. Between 50-80% of patients present with hypercortisolism 
and 40-60% of patients present with excess adrenal androgen production 94. 
Numerous genetic mutations and alterations have been linked to the development of 
ACTs 95. Mutations in TP53 predisposes children to pediatric ACTs (as well as other 
conditions). This is particularly relevant in southern Brazil, which has a 10-fold higher 
rate of pediatric ACTs due to mutations in TP53 96. Levels of insulin growth factor II 
(IGFII) is commonly used as an ACC marker due to its overexpression in 90% of ACCs 
95,97. Alone, mutations that result in increased IGFII levels are not a significant factor for 
ACC development, but these mutations may contribute to ACC progression in 
combination with other factors 95,98. Activating mutations of b-catenin, leading to 
increased activation of Wnt signaling, has been detected in ACC patients 95,99. 
Additionally, mutation in genes shown to regulate or be involved in Wnt signaling 
potentially lead to an increase in ACTs 95. Mutations in other genes including multiple 
endocrine neoplasia 1 (MEN1), mutL homolog 1 (MLH1), mutS homolog 2 (MSH2), 
mutS homolog 6 (MSH6), post meiotic segregation increased 2 (PMS2) and post meiotic 
segregation increased 2 (PRKAR1A) have all been observed in patients with ACCs 95. 
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Alterations in gene expression in ACTs are commonly divided between ACC and ACA 
95. Changes in gene expression frequently seen in ACC are the overexpression of cell 
proliferation and cell cycle genes, such as cyclin E1, cyclin E2, and cyclin dependent 
kinase 2 and 4 (CDK2 and 4) 95,100. Additionally, ACCs have alterations of steroidogenic 
enzymes, including cyp11A1, StAR, cyp17A1, while these enzymes are generally 
upregulated in ACAs 95. Other pathways known to be affected in ACTs include, IGFII 
101, sonic hedgehog (Shh) 102,103, Wnt 95,99, fibroblast growth factor receptor (FGFR) 101, 
and retinoic acid signaling pathways 101. 
1.2.3 Adrenal Development 
The adrenal gland is developed from two different cells types: the adrenal medulla arises 
from neural crest cells, while the adrenal cortex arises from coelomic epithelium 
(urogenital ridge) (Figure 1.4) 104. The adrenogonadal primordium develops from the 
coelomic epithelium, with the presence of developmental regulatory factors, Wilm’s 
tumor 1 (WT-1), and wingless-related mouse mammary tumor virus integration site 4 
(WNT4) 104. In mice, at embryonic day 9 (E9), the key developmental factors 
steroidogenic factor-1 (SF-1) and dosage-sensitive sex reversal-adrenal hypoplasia 
congenital critical region on the X chromosome factor 1 (DAX-1) can be detected in the 
adrenogonadal primordium 104,105. Migration of adrenal progenitor cells from the 
adrenocortical primordium, happens in parallel to an upregulation of SF-1 71,95. The 
importance of SF-1 in adrenal development is demonstrated in studies utilizing knockout 
mice, where SF-1-/- mice lacked adrenal glands and died at birth due to adrenal 
insufficiency 106. The expression of steroidogenic enzymes begins at E11 in mice, 
indicating the possibility of steroidogenesis 105. At approximately E12-14, neural crest 
cells migrate and disperse into the developing adrenal gland, preceding their development 
into the chromaffin cells of the adrenal medulla 107. Encapsulation of the adrenal cortex is 
completed by E14.5 104,105, and adrenal cortex zonation is completed between postnatal 
days (PND) 1-7 in mice 105. The formation of the X-zone surrounding the adrenal 
medulla develops between PND10-14 in mice, and continues to proliferate until PND21 
105. The function of the X-zone and its presence postnatally is still not fully understood 
105. In male mice, the X-zone will disappear at sexual maturity, whereas in females, it 
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remains until the first pregnancy 105. Encapsulation of the medulla by a fibrous tissue 
layer is completed only after complete regression of the X-zone 105. 
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Figure 1.4: Adrenal gland development in mice. 
Urogenital ridge separates into either the (2a) fetal kidney or (2b) the adrenogonadal 
primordia, which derives into the (3a) bipotenial gonads or the (3b) adrenal primordia, 
where steroidogenic enzymes are first detected at E11. Followed by (4) neural crest cells 
migration at E12-14. (5) Zonation occurs at PND1-7, and (6) X-zone development at 
PND14-21. (7) Medulla encapsulation and X-zone regression occurs at sexual maturity in 
males and at the first pregnancy in females. Abbreviation: E, embryonic day; PND, 
postnatal day. 
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While development of the adrenal gland in humans differs from that of the mouse in 
terms of timing of developmental processes, the factors responsible for adrenal gland 
development are thought to be similar between the two species (Table 1.2) 105. In 
humans, migration of coelomic epithelial cells starts during week 5-7 of pregnancy, and 
the formation of the fetal zone, which produces DHEA, begins at week 7 105,107. Despite 
considerable differences in timing of development, the fetal zone in humans is thought to 
be equivalent to the X-zone in mice 105. The adrenal primordia develops at around 8 
weeks 105,107. At 9 weeks, migration of mesenchymal capsular cells to encapsulate the 
adrenal cortex and neural crest cells to form the adrenal medulla 95,105. Regression of the 
fetal zone takes place shortly after birth (postnatal weeks 1-6), followed by the 
encapsulation of the medulla (postnatal months 12-18) 105,107. Complete adrenal cortex 
zonation follows later, around the time of puberty in both males and females (10-20 
years) 105. 
Estrogen and ERs are thought to play critical roles in the development of the adrenal 
gland 108. The discovery of both ERa and ERb in the fetal adrenal cortex suggests a role 
for estrogens in regulating adrenal development and function 108. Upon binding to Ers, 
estrogens induce direct and indirect effects in the fetal adrenal gland, affecting sensitivity 
and responsiveness to ACTH, and altering the synthesis of DHEA 108,109. However, the 
role of estrogens or Ers in programming glucocorticoid synthesis in the fetal adrenal 
gland remains elusive.  
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Table 1.2: Human and mouse adrenal development. 
 Human Mouse 
Migration of coelomic epithelial 
cells 5-7 weeks E9 
Development of the adrenal 
primordia 8 weeks E11 
Migration of neural crest cells 8 weeks E12-14 
Regression of fetal zone/X-zone Postnatal week 1-6 
PND35 (males), after 
first pregnancy 
(females) 
Medulla Encapsulation Postnatal month 12-18 PND35 
Adrenal Cortex Zonation 10-20 years PND1-7 
Abbreviations: E, embryonic day; PND, postnatal day. 
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1.2.4 Adrenal Remodeling and Growth 
Differentiation and renewal of the adrenal cortex zones is not fully understood. However, 
a few theories have been proposed for adrenal zonation: (1) Migration Theory that 
hypothesizes the centripetal proliferation of cells from the outermost zone, ZG, towards 
the ZF, then the ZR and finally undergoing apoptosis at the edge of the adrenal medulla; 
(2) Transformation field theory that postulates the presence of two transformation fields 
between the ZG and ZF and between the ZF and ZR, where proliferation and 
differentiation occurs; (3) Zonal theory that proposes that all proliferation in each zone 
comes from cells located in the same zone 110,111. The most probable theory is migration 
theory 95,107,111,112, which posits that proliferation begins with specialized cells located 
peripherally in the cortex and that these cells will transit inwards through the cortex 
layers, and finally to the medulla border where they undergo apoptosis, a process referred 
to as centripetal displacement 111,112. This process and the location of specific stem cells 
varies in rats, where these cells are likely located in an undifferentiated cell zone (zU), 
between the ZG and ZF 111. Continued remodeling and growth is essential in the adrenal 
gland after birth and throughout life 112-114. These progenitor cells are not only important 
for the development of the adrenal cortex, but also are involved in adrenal cortex 
remodeling in adults 112-114. 
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1.2.4.1 Hedgehog Signaling  
The Hedgehog (Hh) signaling pathway is essential in embryogenesis, adult remodeling 
homeostasis, and carcinogenesis in a variety of tissues 115. The Hh signaling pathway 
regulates genes involved in proliferation, the stem-cell signaling network, stem-cell 
markers, survival, and epithelial-to-mesenchymal transition 115. 
The Hh secretory proteins were first discovered in Drosophila for their role in specific 
embryonic segmentation 116. The three main mammalian HH genes are Sonic hedgehog 
(Shh), Desert hedgehog (Dhh), and Indian hedgehog (Ihh). All are critical for 
development, as demonstrated in loss of function studies that result in structural 
abnormalities and malformations 116,117. Dhh is localized mainly to the gonads, including 
Sertoli cells and granulosa cells. While Dhh-/- mice are viable and do not have a notable 
phenotype, males are infertile 117. Ihh expression is limited to the primitive endoderm and 
prehypertrophic chondrocytes, resulting in 50% lethality in knockout mice, with 
surviving Ihh-/- mice having bone abnormalities, including cortical bone defects and 
aberrant chondrocyte development 117. Shh is more broadly expressed both during 
embryogenesis and later life 117. Mutations in Shh have been shown to cause cyclopia, as 
well as defects in the foregut and ventral neural tube patterning 117. Additionally, defects 
present later in life as malformations of the limbs, ribs, and lungs 117. 
All Hh secretory proteins bind to the Hh receptors, Patched (Ptch) 1 and 2 to activate the 
signaling pathway (Figure 1.5). Patched is a 12-pass transmembrane receptor located on 
the primary cilium of target cells. Co-receptors of the Hh signaling pathway include 
CDON, BOC, and GAS1 115. When not bound, Ptch inhibits another transmembrane 
protein, smoothened (SMO), by keeping it sequestered in the plasma membrane 117-119. 
SMO is a 7-pass G-protein coupled receptor that is also located in the plasma membrane 
of the primary cilium. In the plasma membrane SMO is tethered to a complex containing 
the key Shh transcription factors Gli 117-119. When the Shh pathway is activated, Hh 
prevents Ptch from inhibiting SMO and enables the translocation of SMO into the 
cytoplasm 117-119. Upon SMO translocation, the complex containing the Gli transcription 
factors are released. In mammals, there are three Gli transcription factors (Gli1-3), with 
various activities 117-119. Gli1 and Gli2 are primarily activators of the Shh signaling 
pathway and have similar roles 117-119. However, Gli1 is also responsible for positive 
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feedback of the Shh signaling pathway, and is a direct transcriptional target of Shh 
activation, to extend cellular response 117-119. The activation of SMO blocks proteolysis of 
Gli1 and 2, which leads to accumulation of the full-length activator forms of Gli1 and 
Gli2, ultimately leading to transcription of target genes 117-119. Gli3 is primarily a 
repressor; in the absence of Shh, Gli3 is cleaved into an active repressor form, to inhibit 
transcription of target genes, but the presence of Shh prevents Gli3 cleavage and thus 
inhibits Gli3 activity 117-119. Additional factors known to be involved in the regulation of 
the Shh pathway include suppressor-of-fused protein (Su(fu)) and hedgehog interacting 
protein (Hhip), both of which attenuate Shh signaling 115,118. 
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Figure 1.5: Simplified schematic of the Shh signaling pathway activation. 
The secretory protein Shh, acts in an autocrine/paracrine fashion and binds to Ptch1 
receptor, preventing Ptch1 from inhibiting SMO. SMO is then released from the plasma 
membrane into the cytoplasm, leading to the release of key Shh transcription activators 
Gli1 and Gli2. Gli1/2 translocate to the nucleus where they bind to the promoters of 
target genes to regulate gene expression. Abbreviations: Shh, sonic hedgehog; Ptch1, 
Patched 1; SMO, smoothened.  
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Due to the importance of Shh signaling in development and organ remodeling later in 
life, the Shh signaling pathway has been investigated in both rodent and human adrenal 
glands. Expression of mRNA for Shh, Ptch1, and Gli1 begins at E12.5 in the mouse 
adrenal cortex, and is localized in clusters at the periphery of the adrenal cortex, which 
continues throughout development 112,114,120. Shh, Gli1, 2, and 3 proteins are detected 
throughout development and postnatally in the fetal human adrenal gland, with higher 
expression than is found in adult human adrenal glands 102. In contrast, Werminghaus et 
al. demonstrated undetectable levels of Shh protein in both normal adult adrenal glands 
and adrenocortical carcinomas and adenomas 103. However, protein levels of Gli1 were 
detectable in all adrenal cortex zones, but concentrated in the subcapsular area of the ZG 
of human adult adrenal glands, and was not detectable in adrenocortical carcinomas or 
adenomas 103. While additional studies have also detected mRNA for Shh, Gli1, 2 and 3, 
Ptch1 and SMO in human adrenal glands, adrenocortical carcinomas and adenomas 
102,103. Additionally, there was an upregulation of SHH in both cortisol producing and 
non-cortisol producing adrenal adenomas compared to normal adrenal tissues, suggesting 
that Shh activation is involved in adrenal tumorigenesis 102,103. Moreover, Shh, Gli1, 
Ptch1 and SMO mRNA has been found in human adrenal cortical carcinoma cell lines, 
H295R and H295A102,103. The presence of Dhh or Ihh in the adrenal glands has yet to be 
determined 113. 
Shh and Shh pathway components (Ptch1, SMO, Gli1) mRNA and protein are localized 
in the outer cortex cells, which do not express the steroidogenic enzymes cyp11b1 or 
cyp11b2, during early organogenesis and throughout adulthood in mice 112. This indicates 
the presence of a specialized population of cells in the adrenal cortex that lacks the ability 
to produce steroid hormones 112. This demonstrates the essential role of Shh signaling in 
the development and expansion of the adrenal cortex 114, and supports the theory of 
adrenal growth and remodeling through a centripetal displacement process, where Shh 
containing cells are progenitor cells that differentiate into steroidogenic cells (Figure 1.6) 
112,113. Indeed, previous studies using genetic lineage analyses performed using a 
constitutive Cre model, demonstrated that Shh-positive cells give rise to cortex cells in all 
zones except the medulla 112. Moreover, lineage analysis in adults, shows that cells 
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transition from the outer ZG to the ZF, demonstrating that Shh marks progenitor cells in 
the adrenal cortex during development and remodeling in adults 112,113. 
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Figure 1.6: Migration theory of adrenal gland remodeling in mice. 
Progenitor cells (purple), which are Shh+/Sf-1+/cyp11B2-, signal to Gli1+/cyp11B2- 
capsule cells (red), to differentiate into functional ZG steroidogenic cells (orange). The 
migration theory suggests a centripetal displacement process where ZG cells move 
inward and differentiate into ZF cells (blue) and on to X-zone cells (dark red), before 
undergoing apoptosis at the medulla border. Abbreviations: Shh, sonic hedgehog; Sf-1, 
steroidogenic factor-1; ZG, zona glomerulosa, ZF, zona fasciculata.  
 
 
 
 
 
 
 
 
X-zone 
Progenitor cells 
ZF 
Medulla 
ZG 
Capsule 
 33 
Gli3 mutation was found to be lethal in embryonic mice and to have an adrenal aplasia 
phenotype 121. However, this phenotype was not observed by Laufer, et al. 113. Adrenal 
Shh conditional knockout mice, created with a Sf-1-cre driver, exhibit severe hypoplasia 
and underdevelopment of the adrenal gland, but have no changes in zonation or 
differentiation of the adrenal cortex 112,114,120. There was a significant decrease in both the 
thickness of the adrenal cortex and the capsule in these mice 112,114. These effects were 
visible as early as E13.5, with no visual changes to the adrenal medulla 112,114,120. 
However, despite the reduction in cortex size, the expression of steroidogenic enzymes 
was unaltered in Shh-/- mice 112,114,120. Corticosterone levels were normal until 
approximately one year of age, when they became reduced along with an increase in 
ACTH plasma levels 114. Moreover, Shh-/- mice had reduced levels of proliferating cells in 
their adrenal cortex, with no change in apoptosis levels 114. In H295R cells, blocking Shh 
signaling with the antagonist cyclopamine resulted in decreased proliferation, and 
decreased production of aldosterone and DHEA 103. 
1.2.4.2 Wnt-1 Signaling  
In both fetal and adult adrenal glands, the Wnt/b-catenin signaling pathway is critical for 
adrenocortical homeostasis 122. b-catenin is present in the fetal adrenal cortex, and is 
localized to the ZG subcapsule 122. Mice null for b-catenin in SF-1 expressing adrenal 
cortex cells, show abnormal adrenal development starting at E12.5, resulting in adrenal 
failure 123. b-catenin Sf-1-cre mice, which expressed b-catenin in approximately half of 
their adrenal cortex cells, developed normally 123. However, a thinning of the adrenal 
cortex and decreased steroidogenic function was observed starting at 30 weeks of age 123. 
Additional evidence for the role of Wnt-1/b-catenin signaling in adrenal development and 
function is demonstrated when the signaling pathway is over-activated 123,124. 
Constitutive over-activation of b-catenin results in increased proliferation of 
undifferentiated progenitor cells, with the eventual development of ACTs 123,124. 
Activation of the Wnt signaling pathway is commonly seen in adrenocortical neoplasms 
125,126. The exact mechanism of Wnt/b-catenin signaling in adrenal cortex function and 
development remains unknown 107. However, potential mechanisms include direct 
activation of Dax1 by b-catenin 127 and b-catenin induced inhibition of ZF differentiation, 
supporting the undifferentiated phenotype of progenitor cells 126,128. 
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1.2.5 Sex Specificity in Adrenal Glands 
Female adrenal glands are significantly heavier than those of male mice from weeks 3-11, 
relative to body weight 129. Additionally, female mice have a significantly larger ZF size 
and cell number compared to male mice after 3 weeks of age 129. Both sexes have an X-
zone until approximately week 5 postnatally, when the X-zone starts to recede in male 
mice 129. In female mice, the X-zone persists until after the birth of their first litter, when 
it will start to recess. However, the role of X-zone and the sex-specificity of this zone is 
not fully understood yet 105. Studies investigating corticosterone levels between sexes in a 
variety of species including humans have reached different conclusions with some 
reporting sex differences in corticosterone levels 78,130, while others found no differences 
in corticosterone levels between sexes 129,131-133. Species investigated, time of collection, 
method of collection, and age of animal may all be confounding factors, contributing to 
the disagreement between the studies. Females are commonly shown to have a higher 
corticosterone response to stress, which is also sustained longer than it is in males 78. 
Additionally, female mice have a greater number of lipid droplets stored in the adrenal 
glands than their male counterparts 129, which indicates a potential for different 
steroidogenic activity and capabilities. Additionally, levels of plasma corticosteroid 
binding globulin (CBG) vary between sexes, due to role of estrogen in promoting 
synthesis of CBG 78. After puberty females are reported to have 2 to 5-fold higher CBG 
levels than males 78. Thus, there are numerous sex differences in the growth and 
development in the adrenal gland, but the exact mechanism behind these differences 
remains largely unknown. 
1.3 Adrenal Steroidogenesis 
1.3.1 Steroidogenic Pathway  
Steroidogenesis is the synthesis of all steroid hormones by a variety of P450 enzymes and 
hydroxysteroid dehydrogenases, generally located in the adrenal glands, placenta, and 
reproductive organs 69. However, low levels of steroidogenesis have been reported in 
other tissues134, such as the nervous system 135, skin136, heart 137, and lungs 138. The 
steroid hormones produced in each organ is dependent on the specific steroidogenic 
enzymes expressed in that organ 69. 
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The initial step of adrenal steroidogenesis begins in the adrenal cortex, where cholesterol 
is necessary to produce steroid hormones (Figure 1.7). Most cholesterol for adrenal 
steroidogenesis originates from either high-density lipoprotein (HDL) or LDL in the 
blood and transport of cholesterol into the cell is mediated by SRB1 receptors for HDL or 
LDL receptors for LDL 77. Humans preferentially utilize cholesterol from LDL 
endocytosis, while rodents use cholesterol transported by SRB1 receptors 77. Additional 
free cholesterol can be produced from de novo synthesis, primarily from the endoplasmic 
reticulum 77. Cholesterol in endosomes can be converted into free cholesterol by 
lysosomal acid lipase (LAL) 77,139. Free cholesterol can be released from cholesterol 
esters stored in lipid droplets by hormone sensitive lipase (HSL) 77,139. Re-esterified 
excess free cholesterol by acyl-coenzyme-A-cholesterol-acyl-transferase (ACAT) can be 
stored in lipid droplets for future use 77. 
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Figure 1.7: Cholesterol transport for adrenal steroidogenesis. 
Free cholesterol for adrenal steroidogenesis is generated by 4 sources. (1) de novo 
synthesis from the endoplasmic reticulum; (2) LDL binding to the LDL receptor, which is 
taken up by endocytosis into lysosomes, where it will be synthesized from cholesterol 
esters to free cholesterol by LAL; (3) HDL cholesterol will bind to SRB1, which can be 
immediately used for steroidogenesis or stored in lipid droplets; or (4) HSL provides free 
cholesterol from lipid droplets. Excess cholesterol can be stored in lipid droplets after 
esterification by ACAT. Abbreviations: LDL, low-density lipoprotein; LAL, lysosomal 
acid lipase; HDL, high-density lipoprotein; SRB1, Scavenger receptor B type 1; HSL, 
hormone sensitive lipase; ACAT, Acyl-coenzyme-A-cholesterol-acyl-transferase.  
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Within the adrenal cortex cells, steroidogenesis begins within the mitochondria. The rate-
limiting step of adrenal steroidogenesis is the transport of free cholesterol from the outer 
mitochondrial membrane (OMM) to the inner mitochondria membrane (IMM), which is 
facilitated by the protein StAR (Figure 1.8) 140. Once cholesterol is in the mitochondria, 
it can be converted to pregnenolone by the P450 enzyme, cyp11A1 (formally referred to 
as P450 side chain cleavage; P450scc). Cyp11A1 conversion is a process of 3 reactions 
(1) 22-hydroxylation of cholesterol; (2) 20-hydroxylation of 22(R)-hydroxycholesterol; 
and (3) oxidative scission of the C20-22 bond 77,141. Conversion of cholesterol to 
pregnenolone is critical for the production of all steroid hormones, so knockout of 
cyp11A1 or mutations in this gene result in loss of steroidogenic activity 141. For the 
synthesis of glucocorticoids, pregnenolone is converted to progesterone by 3β-
hydroxysteroid dehydrogenase (3β-HSD). In primates that synthesize mainly cortisol but 
also low levels of corticosterone, Cyp17 converts pregnenolone to 17a-hydroxylase 
pregnenolone and converts progesterone to 17a-hydroxylase progesterone. Progesterone 
or 17a-hydroxylase progesterone will then be further converted to 11-
deoxycorticosterone or 11-deoxycortisol by Cyp21 in rodents and humans, respectively 
69. Finally, corticosterone/cortisol will be synthesized from 11-deoxycorticosterone/11-
deoxycortisol by an adrenal specific P450 enzyme, Cyp11B1. Corticosterone/cortisol can 
either exit the adrenal gland in the plasma, bound to CBG and transported to most target 
organs throughout the body 78 or can be further converted by Cyp11B2 to aldosterone in 
the ZG of the adrenal cortex 142. 
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Figure 1.8: Steroidogenic pathway involved in glucocorticoid synthesis. 
Steroidogenesis starts with the transport of free cholesterol from the outer mitochondria 
membrane to the inner mitochondria membrane by StAR, which can then be further 
converted to all the major steroid hormones. Abbreviations: StAR, steroidogenic acute 
regulatory protein; cholesterol side chain cleavage enzyme, cyp11A1, 3β-HSD, 3β-
hydroxysteroid dehydrogenase; cyp21, 21-hydroxylase; cyp11b1, steroid 11β-
hydroxylase; cyp11b2, aldosterone synthase; cyp17, cytochrome P450 17A1; cyp19, 
aromatase; 17β-HSD, 17β-hydroxysteroid dehydrogenases.  
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1.3.2 Steroidogenic Acute Regulatory Protein 
StAR is the rate-limiting step in steroidogenesis, due to its essential role of transporting 
cholesterol from the OMM to the IMM for steroidogenesis. Mutations of StAR in humans 
produce congenital lipoid adrenal hyperplasia, resulting in a lack of steroid hormone 
production that requires life-long hormone therapy 143. Moreover, StAR knockout mice 
lack the ability to synthesize steroid hormones, and accumulate cholesterol in both the 
adrenal glands and gonads 144-147. StAR-/- mice have external female genitalia and fail to 
grow after birth 147. A proportion of StAR-/- mice die shortly after birth due to respiratory 
distress, and the remainder die a week after birth from an imbalance in fluid and 
electrolytes, a result of secondary adrenal insufficiency 147. While StAR-/- mice can be 
rescued by treatment with steroid hormones (corticosterone and aldosterone), they retain 
notable abnormalities in adrenal and gonad structure and function 146. Steroidogenesis is 
not completely abrogated in StAR-/- mice until the accumulation of lipid droplets in 
adrenal and gonads builds up enough to destroy steroidogenic cells 146. 
StAR originates from a 37-kDa StAR pre-protein with an N-terminal mitochondrial 
targeting sequence that directs it to the mitochondria 77,141. The 37-kDa StAR cytoplasmic 
precursor has a short half-life, and is rapidly degraded if not imported into the 
mitochondria (Figure 1.9) 141. Cleavage of the 37-kDa StAR pre-precursor into a 30-kDa 
“mature” molecule by removal of the N-terminus occurs at the OMM 148. Although the 
30-kDa protein (referred to in this thesis only as StAR) is considered “mature”, the 
removal of the N-terminus is not necessary for activation 77. The cleavage, however, 
seems to contribute to the localization of StAR on the OMM, which does determine its 
activity 77,149. Thus, the time of StAR residency on the OMM is directly proportional to 
its activity 77,141. StAR contains a sterol binding pocket allowing it to transport a single 
cholesterol molecule from the OMM to the IMM. 150. However, each StAR molecule will 
transport hundreds of cholesterol molecules before it undergoes cleavage and removal 
from the OMM, terminating its activity 141. There are currently four proposed models to 
account for StAR’s ability to transport cholesterol 151. (1) Contact sites: the 37-kDA 
StAR forms contact sites with the OMM and IMM that permit cholesterol to flow down a 
concentration gradient into the mitochondrial matrix 151,152. (2) Desorption: StAR 
“desorbs” cholesterol at the OMM, permitting its entry into the intra-mitochondrial space 
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(IMS), potentially as micro droplets 151,153. There is little evidence to support this theory, 
since micro droplets of cholesterol have not been observed 151. (3) IMS Shuttle: StAR acts 
in the IMS to shuttle cholesterol from the OMM to the IMM 151,154. This theory is no 
longer accepted, due to the observation of StAR activity on the OMM 151. (4) Molten 
Globule: StAR undergoes a conformational change at the OMM caused by protonated 
phospholipids 149,151. This is confirmed by the dependence of StAR on a proton pump on 
the mitochondria for its activity 151,155.  Additionally, at the OMM StAR interacts with a 
multi-protein complex containing translocation protein (TSPO, previously the peripheral 
benzodiazepine receptor; PBR), voltage-dependent anion channel 1, and phosphate 
carrier protein, which may all be involved in StAR-mediated cholesterol transport 
148,149,156,157. The activity of steroidogenesis is partially controlled by the phosphorylation 
of StAR at Ser194/5, which doubles its rate of cholesterol transport 77,158. In the absence 
of StAR, steroidogenesis is possible when cholesterol transport occurs with the help of 
metastatic lymph node 64 protein (MLN64) using a yet to be determined mechanism 159. 
This MLN64 mediated process of cholesterol transport occurs mostly in the human 
placenta, which lacks StAR protein, and has about 50-60% of the cholesterol transport 
ability of StAR 159. 
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Figure 1.9: Synthesis of steroidogenic acute regulatory protein (StAR). 
(1) Transcription of StAR occurs in the nucleus of steroidogenic cells. (2) StAR mRNA 
is then transported to the mitochondria where it binds to AKAP149, which is involved in 
its translation into a 37-kDa pre-protein and phosphorylated by PKA at Ser194/5. (3) 37-
kDa StAR will then interact with the multi-protein complex, TSPO on the outer 
mitochondria membrane, where the n-terminus of StAR is cleaved. StAR then facilitates 
the transport of cholesterol from the outer mitochondria membrane to the inner 
mitochondria membrane. (4) After cholesterol transport, 30-kDa StAR will enter the 
mitochondria where it will be degraded. Abbreviations: StAR, steroidogenic acute 
regulatory protein; AKAP149, A-kinase anchor proteins; PKA, protein kinase A; TSPO, 
Translocator protein.   
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1.3.2.1 Regulation of StAR 
Due to the essential role of StAR in facilitating cholesterol transport from the OMM to 
the IMM for steroidogenesis, the regulation of this protein is of great importance. The 
regulation of StAR is not fully understood but has been shown to be quite complex, 
involving numerous hormones, transcription factors, and receptors 160,161. 
1.3.2.1.1 Epigenetic Regulation of StAR 
StAR expression is affected directly and indirectly by epigenetic modifications, such as 
histone modifications, and micro-RNA (miRNA) 162-166. For example, induction of StAR 
was associated with acetylation of histone 3 but not histone 4 on the proximal StAR 
promoter in MA-10 cells and in primate granulosa cells after stimulation 162,163. 
Additionally, epigenetic factors can have indirect effects on StAR expression by altering 
transcription factors known to bind the StAR promoter, such as miRNA-133b inhibition 
of the negative transcription factor forkhead box L2 (Foxl2), which results in increased 
StAR transcription 164. 
1.3.2.1.2 Transcriptional Regulation of StAR 
The first 150 bases of the proximal StAR promoter are highly regulated by numerous 
transcription factors. Positive regulators of StAR transcription include SF-1, CCAAT-
enhancer-binding protein β (C/EBPβ), GATA-4, specificity protein 1 (Sp1), sterol 
regulatory element binding protein (SREBP), CREB/CREM, and AP-1 140,162,167, all of 
which have numerous putative binding sites on the StAR promoter 140,167. Additionally, 
DAX-1, Foxl2 and Yin Yang 1 (YY1) negatively regulate transcription of StAR mRNA. 
Transcription factor expression and regulation of StAR have been shown to be cell/tissue-
specific as well as time dependent 162. 
SF-1 not only plays a critical role in adrenal development, it is also known as a master 
regulator of steroidogenesis 168. There are six binding sites for SF-1 on the StAR 
promoter, where it can regulate both basal and stimulated StAR transcription 140,167. The 
SF-1 binding sites -43/-37, -102/-96 and -105/-99 have all been shown to be essential for 
both basal and stimulated StAR regulation in reproductive cells 167. Mutations in any SF-
1 binding sites, result in a significant decrease, but not an elimination in cAMP induced 
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StAR activity, demonstrating the involvement of other transcription factors or regulatory 
responses in StAR expression. 
These transcription factors are able to act alone or in combination by binding to the StAR 
promoter 167. It is suggested that C/EBPβ can form a complex with SF-1 on the StAR 
promoter, as well as interacting with Sp1 to promote StAR transcription 140,167. 
Additionally, SF-1 can interact with Sp1, and C/EBPβ cooperates with GATA-4 to 
regulate StAR expression, 167. Therefore, the regulation of StAR transcription is thought 
to involve the interaction of numerous transcription factors at the StAR promoter region. 
1.3.2.1.3 Post-transcriptional Regulation of StAR  
Initially, StAR was thought to be mainly transcriptionally regulated, however recent 
evidence points to a role of post-transcriptional regulation of StAR 160. The stability of 
StAR mRNA and post-translational regulation of StAR have been investigated 160. 
Currently, no known proteins have been shown to bind to StAR mRNA to regulate its 
stability, however, possible candidates include the mRNA stabilizing proteins, TPA-
induced sequence 11b (Tis11b) and HuR, which are expressed in steroidogenic cells 160. 
Additionally, StAR mRNA may be targeted by proteins such as mevalonate kinase, 
DAX-1 and A-kinase anchoring protein 121/149 (AKAP121/149) that alter its rate of 
translation 160. AKAP121/149 contains an N-terminal KH domain that targets and recruits 
StAR mRNA to its location at the OMM where it can be translated 169. StAR protein 
expression at the OMM has been shown to be enhanced by AKAP121/149 in MA-10 
cells 170. In addition, AKAP121/149 has been demonstrated to recruit PKA, which 
phosphorylates StAR to increase its activity 170. 
The N-terminal of the 37-kDa StAR directs it to the mitochondria, but it may also 
destabilize the protein, promoting its degradation and contributing to its short half-life 
152,160. StAR degradation in the cytoplasm has been shown to be extremely rapid in many 
tissues 171. Proteasome-mediated degradation of the 37-kDa StAR protein has been 
demonstrated, and it is suggested that this may occur without ubiquitinylation of StAR 171. 
StAR physically and/or functionally interacts with numerous proteins at or around the 
OMM, including cyclin dependent kinase-5 (CDK5), mitochondrial kinases (MEK) 1/2, 
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PAP7, TSPO, HSL 160. While these proteins and others could potentially contribute to 
StAR’s expression and activity, more evidence is needed to understand StAR–protein 
interactions. 
1.4 Effects of BPA on Steroidogenesis 
1.4.1 Male Reproductive Steroidogenesis  
Due to its estrogenic nature, the effect of BPA on the male reproductive system has been 
the subject of considerable research effort. BPA exposure, both during the prenatal period 
and during adulthood results in increased prostate size 6,172. Rodent studies have 
demonstrated that exposure to BPA during the developmental period alters 
spermatogenesis and reduces sperm quality in adult offspring 173. Additionally, BPA 
adversely affects androgen production, which is essential for functional spermatogenesis 
173. Decreases in testosterone levels and/or steroidogenic enzymes was observed in 
rodents exposed to BPA prenatally, as well as during the postnatal period 173-176. 
Investigation of the effects of BPA on the rate limiting step of steroidogenesis, StAR, in 
the male reproductive system yielded inconsistent results that vary between model 
systems (Table 1.3 and 1.4). In male rats, Qui et al. 2003 177 observed an increase in 
StAR and cyp11A1 gene expression in the testis after acute BPA exposure. In contrast, 
D'Cruz, et al. 175 demonstrated that BPA exposure resulted in decreased protein 
expression of StAR in male rats, a finding in agreement with two other studies showing 
that acute BPA exposure decreased StAR levels in testes 174,178. Chouhan, et al. 178 
concluded that the decrease in StAR protein after BPA exposure could be attributed to a 
BPA-induced increase in oxidative stress, resulting in increased inducible nitric oxidative 
synthase (iNOS). Moreover, both perinatal and acute exposure to BPA significantly 
inhibited StAR in the testis of fetal and offspring rodents 179-181. However, BPA treatment 
for 17 h did not significantly alter levels of StAR in primary mouse Leydig cells 182. 
Therefore, more research is needed to understand the variability and mechanism behind 
the effects of BPA on StAR in the male reproductive system. 
1.4.2 Female Reproductive Steroidogenesis 
Due to BPA activity as an estrogen mimicking chemical, the effects of BPA on the 
female reproductive system and fertility has also been investigated. Of interest is a study 
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by Ikezuki, et al. 59 that used enzyme-linked immunosorbent assays (ELISA) to determine 
BPA levels of 1-2 ng/mL in 36 human follicular fluid samples. In contrast, when 
measuring BPA with high-performance liquid chromatography and mass spectrometry 
(HPLC-MS), no BPA was detected in the five human follicular samples examined 183. 
Ovarian steroidogenesis is fundamental for estrogen production, which is essential for 
ovarian function 184. In ovaries, theca cells use cholesterol to produce testosterone via the 
steroidogenic pathway, which is then further converted to estrogen in granulosa cells by 
the enzyme aromatase (cyp19A) 184. The effects of BPA on estrogen, androstenedione 
and DHEA have been widely reported in the literature 184. In vitro studies have 
demonstrated increased estrogen synthesis, and as shown by Peretz, et al. 185, impairment 
of follicular growth. However, BPA exposure in rodent models result in inconsistent 
outcomes184. Gamez, et al. 186 reported increased estradiol and FSH levels in pre-pubertal 
female rats exposed to 3µg/kg/d BPA prenatally. In contrast, ovine female offspring 
prenatally exposed to three different BPA doses (0.05, 0.5, or 5mg/kg bw/day) had no 
changes in estradiol levels, but did have a shortened time of estradiol surge compared to 
the LH surge peak, indicating potential fertility problems 187. Epidemiological studies 
have also found that higher BPA levels lead to higher serum estradiol levels in most cases 
184. However, few human studies employ healthy female subjects, tending to focus on 
women attending clinics for in vitro fertilization or other reproductive conditions 184. 
Thus, the effects of BPA on ovarian steroidogenesis and function appear to be dose-, 
species- and time-dependent, with more investigation necessary to provide conclusive 
results. 
Numerous investigators have looked at levels of the key steroidogenic protein StAR, 
since it is involved in all steroid hormone production as well as being the rate-limiting 
step in steroidogenesis (Table 1.3 and 1.4). BPA inhibits StAR in cultured mouse 
ovarian follicles in a variety of mouse strains 185,188,189. Conversely, BPA increases 
cyp11A1 and StAR mRNA in rat ovarian theca-interstitial (T-I) cells and granulosa cells 
190. However, BPA had no effect on StAR mRNA in luteinized human granulosa cells 191. 
In vitro studies showed that BPA inhibited StAR protein expression in T-I and granulosa 
cells 192. In contrast, Xi, et al. 179 found no change in ovarian StAR expression with either 
prenatal or postnatal BPA exposure. Thus, the effects of BPA exposure on steroidogenic 
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enzymes are animal- and tissue-specific and vary depending on the type of BPA 
exposure. Nevertheless, it is important to note that regulation of steroidogenesis in 
reproductive tissues differs from that of the adrenal gland. 
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Table 1.3: Effects of BPA on testicular and ovarian StAR expression in vitro. 
Cell type Time of BPA Dose Results Reference 
Primary antral 
follicles from 
FVB, and 
C57BL/6 
24-96 h 1-100 µg/ml Decreases mRNA of 
StAR after 72-96 h after 
10-100 µg/ml BPA. 
189 
Primary CD-1 
mouse antral 
follicles 
24-96 h 1-100 µg/ml Decreases mRNA of 
StAR at 72-96 h with 
10-100 µg/ml 
188 
Primary mouse 
follicles from 
FVB mice 
120 h 4.4-440 µM  Decreases StAR after 
440 µM 
185 
Primary rat theca-
interstitial and 
granulosa cells 
72 h  10-7-10-4 M Increases StAR mRNA 
after 10-5-10-4 M in 
theca cell and 10-4 M in 
granulosa cells 
190 
 
 
 
 
Luteinized human 
granulosa cells 
48 h 0.02, 0.2, 2, 
20 µg/ml 
No effect on StAR 
mRNA 
191 
Primary culture of 
mouse leydig 
cells 
17 h 10 µM No effect on StAR 
mRNA  
182 
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Table 1.4: Effects of BPA on testicular and ovarian StAR expression in vivo. 
Animal 
Model Tissue 
Time of 
exposure 
Dose and 
method Results Reference 
Swiss 
albino male 
mice 
Testes 60 days  IP injection 
of 0.5, 50 and 
100 µg/kg 
body 
weight/day 
Decrease StAR 
protein at all 
doses  
178 
Wistar/ST 
male rats 
Testes 42 days  SC injections 
of 20, 100, or 
200 mg 
BPA/kg/day 
StAR mRNA and 
protein decreased 
with 100 and 200 
mg dose 
174 
Wistar 
male rats 
Testes 45 days  Gavaged 
0.005, 0.5, 
50, and 500 
µg/kg bw/day 
Decreased StAR 
protein at all 
doses  
 
175 
Sprague 
Dawley 
male Rats 
Testes 56 days  Gavaged 
0.0005, 0.5, 5 
mg/kg/bw 
Increases StAR 
mRNA and 
protein at 
5mg/kg/bw dose 
177 
 
Sprague 
Dawley 
female rats 
Ovary 90 days  Gavaged with 
0.001, or 0.1 
BPA mg/kg 
bw 
 
Decrease StAR 
protein at all 
doses  
192 
Sprague-
Dawley 
rats  
Fetal 
testes 
E11-20 SC injections 
of 0.02, 0.5, 
or 400 
mg/kg/day  
Decreased StAR 
mRNA at 400 
mg/kg/day 
180 
ICR Mice Offspring 
adult 
testes 
E1-5 20 µg/kg/day 
orally 
StAR mRNA 
decreased at PND 
35-50 
181 
CD-1 mice  Ovary 
and 
testes  
Cohort 
A: E1-
PND 49 
Cohort B: 
PND 20-
49  
Gavaged 
Cohort A: 
12-50 
mg/kg/day 
Cohort B: 25-
50 mg/kg/day 
Cohort A: 
decreased StAR 
mRNA and 
protein at 
50mg/kg/day in 
testes, no change 
in ovaries 
Cohort B: no 
change in StAR 
mRNA 
179 
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1.4.3 Adrenal Steroidogenesis 
Due to the essential role of glucocorticoid in maintaining whole body homeostasis, 
epidemiological studies have associated high levels of BPA with HPA dysfunction 57,193. 
A recent study by Giesbrecht, et al. 57 demonstrated that pregnant women with high 
urinary BPA (1.66-43.20 ng/mL) had lower waking cortisol levels and flatter diurnal 
cortisol rhythms, providing evidence for the potential of BPA to alter the HPA axis and 
cortisol response in adults 57. The offspring of the same women were examined after 
parturition, to determine the effects of high BPA exposure on infant cortisol levels and 
reactivity 193. This study showed an association between high maternal BPA levels and 
increased basal salivary cortisol levels in female infants, but decreased cortisol levels in 
male infants compared to infants exposed to low BPA levels 193. Additionally, cortisol 
reactivity was decreased in female infants and increased in male infants exposed to high 
prenatal BPA 193. Taken together, these studies shown an association of chronic prenatal 
exposure to BPA with dysfunction of the HPA-axis in humans 57,193. 
The effects of BPA on plasma levels of corticosterone have been evaluated in numerous 
experimental animal studies, however the effects appear to be dependent on the animal 
used, dosage of BPA, timing and length of exposure, route of exposure, and time of 
corticosterone measurement (Table 1.5). The sex-specificity of BPA effects on 
corticosterone levels remain disputed. An increase in corticosterone levels in male but not 
female adult offspring was seen in rats pre- and post-natally exposed to 2 µg/kg 
subcutaneous injections of BPA from E10 to PND7 80,81. However, an increase in 
corticosterone levels was seen in female, but not male, mid-adolescence rat offspring 
when pre- and post-natally exposed to 40 µg/kg BPA in orally throughout pregnancy and 
lactation 194,195. No changes in corticosterone were seen in either sex of rats at PND21 
when gavaged with 2.5 or 25 µg/kg/day BPA from E6 to PND21 196. 
The effects of acute BPA exposure on adrenal steroidogenic enzymes have been 
demonstrated in the adrenal mouse cell line Y-1, as well as in rats acutely exposed to 
BPA 197. Lan et al. 197 demonstrated that in vitro exposure to BPA levels from 50-10,000 
nM was sufficient to elevate cyp11A1 protein levels in a dose-dependent manner, but did 
not affect SF-1 levels 197. Additionally, this group showed that daily subcutaneous BPA 
injections of 0.5 µg/kg for three days resulted in increased plasma corticosterone and 
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adrenal cyp11A1 protein levels in male Sprague-Dawley rats 197. These studies show that 
BPA alters adrenal steroidogenesis in cell and animal models; however, the effects of 
prenatal BPA exposure on adrenal steroidogenesis have yet to be investigated. 
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Table 1.5: Effects of BPA on basal corticosterone levels. 
Animal 
Model 
Time of 
exposure 
Dose and 
Method 
Age of 
evaluation 
Basal 
Corticosterone 
levels 
Reference 
C57BL/6 E7.5-E18.5 
25 mg 
BPA/kg in 
food 
E18.5 No change 68 
Sprague-
Dawley rats E10-PND7 
orally 
administered 
2 µg/(kg/day) 
of BPA 
PND80 Increased in males 
81 
Sprague-
Dawley rats 
E6-E21 
prenatally, 
PND1-
PND21 
directly to 
pup 
Orally 
gavaged 2.5 
and 25 
µg/kg/day 
PND21 No change in either sex 
196 
Sprague-
Dawley rats 
Throughout 
pregnancy 
and 
lactation 
orally 
gavaged 
40 µg/kg/day 
of BPA 
 
PND40-50 Increased in females 
198 
Wistar rats 
Throughout 
pregnancy 
and 
lactation 
orally  
administered 
40 µg/kg/day 
of BPA 
PND46 
Increased in 
females and not 
males 
195 
Wistar rats 
Throughout 
pregnancy 
and 
lactation 
orally 
administered 
40 µg/kg/day 
of BPA 
PND46 
Increased in 
females but not 
males 
194 
Sprague-
Dawley rats E10-PND7 
2µg/(kg/day) 
BPA  
SC injections 
PND80 
Increased in 
males and not 
females 
80 
Deer mice 
2 weeks 
prior to 
mating and 
throughout 
pregnancy 
and 
lactation 
50mg of 
BPA/kg feed 
weight 
PND90 No changes in males 
199 
Sprague-
Dawley rats 3 days 
0.5µg/kg BW 
BPA 
 SC injections 
8 weeks Increased in males 
197 
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1.5 Rationale 
BPA as an EDC in numerous tissues is well established 2,10,15. Moreover, the potential 
adverse effects of in utero BPA exposure on fetal development and the long-term 
consequences of this exposure is of great concern 2,6,13. Indeed, prenatal BPA exposure 
has a wide range of adverse health effects, including reproductive 179-181, cardiovascular 
200,201, respiratory 68,202, immunological 203,204, metabolic 66,67,205, behavioral and 
neurological 11 disorders, in both the fetus and adult offspring. Thus, brief exposure to 
BPA during critical periods of development can have lifelong health consequences. 
The adrenal gland plays a critical role in production of glucocorticoids which are 
necessary in maintaining whole body homeostasis. Furthermore, the adrenal gland is 
highly vulnerable to environmental toxin insult due in part to its potential for free radical 
generation during steroidogenesis, ability to take up lipophilic agents, high vascularity 
allowing delivery of toxins, and high levels of CYP enzymes available to activate toxins 
206,207. Given the above, my thesis focuses on the long-term effects of prenatal BPA 
exposure on adrenal gland development and steroidogenic function in adulthood. 
Prenatal BPA exposure has been shown to increase plasma glucocorticoid levels in 
offspring, in a sex-specific manner. However, the precise nature of these sex-specific 
effects on plasma corticosterone levels remains obscure 80,194,195,198. Moreover, whether 
the BPA-induced increases in plasma corticosterone levels are a result of enhanced 
adrenal steroidogenesis is not known. Importantly, whether prenatal BPA exposure alters 
adrenal development remains to be demonstrated. Therefore, this thesis addresses these 
important questions. 
1.6 Hypothesis 
I hypothesize that prenatal exposure to BPA disrupts adrenal gland development and 
steroidogenic function in adult mouse offspring.  
1.7 Objectives  
i. To determine the effects of prenatal BPA exposure on adrenal gland development, 
and adrenal steroidogenic function in vivo. 
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ii. To determine the molecular mechanisms that underlie the BPA-induced aberrant 
adrenal gene expression in vitro. 
iii. To determine the molecular mechanisms underlying the BPA-induced aberrant 
adrenal gland development in vitro. 
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2 PRENATAL EXPOSURE TO BISPHENOL A DISRUPTS 
STEROIDOGENESIS IN ADULT MOUSE 
OFFSPRING1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 Reproduced (adapted) from: Medwid S, Guan H, Yang K (2016) Prenatal exposure to 
bisphenol A disrupts steroidogenesis in adult mouse offspring. Environ Toxicol 
Pharmacol. 43: 203-8 
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2.1 Introduction 
Bisphenol A (BPA) is a ubiquitous endocrine disrupting chemical, being present in 
polycarbonate plastics, epoxy resins, paper receipts, and cardboards, as well as water and 
air samples 1-3. Of foremost concern is exposure to BPA during the critical period of 
organ maturation 4. Indeed, BPA has been detected in placental tissues and fetal blood, 
demonstrating BPA’s ability to cross the placenta and reach the fetus 3,5. Numerous 
human epidemiological studies have demonstrated an association between gestational 
exposure to BPA and pregnancy complications, male genital abnormalities, childhood 
obesity, childhood asthma and altered neurological development in children 6. 
Furthermore, in vivo animal studies have shown that developmental BPA exposure results 
in a wide range of adverse effects, including reproductive, cardiovascular, 
immunological, metabolic, behavioural, and neurological disorders as well as certain 
cancers in adult offspring. In addition, many of these adverse effects are sex specific 3,4,7. 
 
Due to the critical role of glucocorticoids (cortisol in humans, and corticosterone in 
rodents) in maintaining whole body homeostasis, the effects of BPA on the 
hypothalamic-pituitary-adrenal axis had been examined previously. It was found that 
maternal exposure to BPA during pregnancy and lactation resulted in increased basal 
corticosterone levels in juvenile female, but not male rats 8-10. Furthermore, perinatal 
BPA exposure led to abnormal adrenal cortex structure, including increased adrenal gland 
weight in females, accompanied by a reduction in the zona reticularis and hyperplasia of 
the zona fasciculata in both sexes 8. In contrast, Chen, et al. 11 reported that prenatal BPA 
exposure resulted in increased corticosterone levels in adult male rats only. Thus, the 
precise nature of these sex-specific effects of developmental exposure to BPA on 
circulating corticosterone levels remains obscure. Importantly, whether the BPA-induced 
increases in circulating corticosterone levels are a result of enhanced adrenal 
steroidogenesis is unknown. Therefore, the present study was undertaken to address these 
two important questions. 
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2.2 Materials and Methods 
2.2.1 Animal Experiments 
The use of animals in this study was approved by the Council on Animal Care at the 
University of Western Ontario, following the guidelines of the Canadian Council on 
Animal Care. Breeding pairs of adult C57BL/6 mice were purchased from Charles River 
Laboratories (Wilmington, MA). To minimize environmental BPA exposure, mice were 
housed in polypropylene cages with glass water bottles. Mice were allowed food and 
water ad libitum, and maintained in humidity and temperature-controlled rooms on a 
12 h/12 h light-dark cycle. Female mice were placed overnight with males, and detection 
of vaginal plug the next morning indicated pregnancy, and marked as embryonic day 0.5 
(E0.5). Pregnant dams were fed either a control diet (phytoestrogen-free food pellets 
supplemented with 7% corn oil; TD.120465, Harlan Teklad, Madison, WI) or the control 
diet supplemented with 25 mg BPA/kg feed weight (equivalent to 5 mg BPA/kg body 
weight; TD.120466, Harlan Teklad, Madison, WI) from E7.5 to postnatal day (PND) 0.5. 
The gestational age of E7.5 was chosen as the start of the feeding regime in order to 
avoid any confounding effects of BPA on embryo implantation. After birth, both control- 
and BPA-fed dams were switched to regular chow for remainder of the study. Pups were 
weaned on PND 21, separated by sex and fed regular chow. Five litters of control and 
BPA were used, with number of pups between 6 and 11 pups per litter. Litters were 
culled at 5 pups per sex per litter. They were group housed by litter, experimental 
treatment and sex. Offspring were sacrificed between 8 and 10 weeks of age using carbon 
dioxide asphyxiation. Blood samples were collected via cardiac puncture in heparinized 
capillary tubes (Fisher brand Cat. No. 22-260-950), and centrifuged at 2000g for 10 min 
at 4 °C. Plasma was then harvested were stored at −80 °C. Adrenal glands were dissected, 
weighed, snap-frozen in liquid nitrogen, and stored at −80 °C. All sacrifices and sample 
collection were done between 9:00–11:00 am. 
2.2.2 Western Blot Analysis  
Due to the limited tissue quantity (i.e., the tiny size of mouse adrenal glands), we made a 
strategic decision to determine changes in protein, rather than mRNA, abundance 
following exposure to BPA during critical periods of adrenal gland development. This is 
because information on alterations in protein levels is more biological meaningful. 
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Furthermore, the limited tissue availability also precluded the possibility of conducting 
enzyme activity assays, which would require greater amounts of tissues in comparison to 
western blot analysis. 
 
Levels of various proteins were analyzed using standard western blot analysis, as 
previously described 12. Briefly, sodium phosphate buffer, (pH 7.0), was used at a 10 
times volume dilution to hand homogenize 2–3 adrenals gland from the same sex and the 
same litter before being mixed with equal amounts of SDS gel loading buffer (50 mM 
Tris-HCL, pH 6.8, 2% wt/vol SDS, 10% vol/vol glycerol, 100 mM DTT and 0.1% wt/vol 
bromophenol blue) to be loaded to a standard 10% SDS-PAGE gel. Protein was then 
transferred to a PVDF transfer membrane (Amersham Hybond-P, Cat. No. RPN303F, GE 
Healthcare Lifesciences, Baie D'Urfe, QC), and blocked overnight with 5% milk in TTBS 
(0.1% vol/vol Tween-20 in TBS) to decrease non-specific antibody binding. Membranes 
were then probed with primary antibodies (Table 2.1) for 1–2 h at room temperature. 
Washing was done with TTBS, 3 × 10 min before labeling with horseradish peroxidase-
labeled rabbit secondary antibody (Table 2.1), for 1 h at room temperature. After 
3 × 10 min TTBS washes, proteins were detected using ECL and visualized using a 
chemiliminescence (Cat. No. WBLUR0500, Luminata Crescendo, Western HRP 
Substrate; Millipore, Etobicoke, ON) and captured on the VersaDoc Imaging System 
(BioRad, UK). Densitometry was performed using Image Lab Software, comparing 
levels of proteins expressed as percent of controls. 
 
 
 
 
 
 
 
 
 
 
 
 76 
Table 2.1: Primary and secondary antibodies used for western blotting. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Antibody Company Catalog Number Dilution Used 
Perilipin Cell Signaling 3470 1:1000 
StAR Santa Cruz Sc-25806 1:4000 
Cyp11A1 Bioss Bs-3608R 1:200 
SF-1 Abcam Ab168380 1:1000 
GAPDH Imgenex IMG-5567 1:10000 
Anti-Rabbit R&D systems HAF008 1:3000 
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2.2.3 Hormone Assays 
Levels of corticosterone and ACTH in plasma samples (plasma from one litter and the 
same sex were pooled, and used as one sample) were determined with an ELISA Kit 
following the manufacturer’s instructions (corticosterone: Abcam, ab108821, 1:60 
plasma dilution, Toronto, ON; ACTH: Phoenix Peptide EKE-001-21, 1:1 plasma dilution, 
Burlingame, CA). To eliminate inter-assay variations, all samples were analyzed in 
triplicate in one assay, and the intra-assay coefficient of variation was <5%. 
2.2.4 Statistical Analysis 
Results are presented as mean ± SEM of four to five different litters, as indicated in 
figure legends. Data were analyzed using two-way ANOVA followed by Tukey’s post-
hoc test, or Student’s t-test as indicated. Significance was set at p < 0.05. Calculations 
were performed using Graphpad Software Prism version 6. 
2.3 Results 
2.3.1 Effects of prenatal BPA exposure on adrenal gland weight 
To determine if prenatal BPA exposure affected body weight, mice were weighed at 8 
weeks. No significant differences in body weight were observed in either sex of BPA-
exposed and non-exposed control mice (Figure 2.1A & B). To investigate if prenatal 
BPA exposure resulted in altered adrenal gland weight, the weight of adrenal glands and 
the ratio of adrenal gland weight to body weight were determined. An increase in adrenal 
gland weight was observed in both male (P < 0.05) and female (P < 0.01) mice prenatally 
exposed to BPA when compared with controls (Figure 2.1C & D). Furthermore, the ratio 
of adrenal gland weight to body weight was significantly increased in both BPA-exposed 
male (P < 0.05) and female (P < 0.01) mice (Figure 2.1E & F). 
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Pregnant mice were fed a control diet (phytoestrogen free food pellets) or the control diet 
supplemented with 25 mg BPA/kg food pellets from E7.5 to birth. At eight weeks of age, 
offspring were sacrificed, body weight (A & B) and adrenal gland weight (C & D) were 
recorded, and adrenal gland to body weight ratio (E & F) was then calculated. Data are 
presented as mean ± SEM (n = 16–22; *P < 0.05, **P < 0.01, vs. control). 
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Figure 2.1: Effects of prenatal BPA exposure on adrenal gland weight. 
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2.3.2 Effects of prenatal BPA exposure on basal plasma 
corticosterone and ACTH levels 
To determine if prenatal BPA exposure affected adrenal plasma corticosterone, plasma 
corticosterone levels were measured using ELISA. We found that corticosterone levels 
were significantly increased in both male (P < 0.01) and female (P < 0.05) mice 
prenatally exposed to BPA when compared to control mice (Figure 2.2A). To ascertain if 
elevated corticosterone levels were a result of hyper-pituitary activity, plasma ACTH 
levels were measured with ELISA. We observed no differences in plasma ACTH levels 
between control and prenatally BPA-exposed mice (Figure 2.2B). 
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Pregnant mice were fed a control diet (phytoestrogen free food pellets) or the control diet 
supplemented with 25 mg BPA/kg food pellets from E7.5 to birth. At eight weeks of age, 
offspring were sacrificed, and plasma samples were collected. Plasma levels of 
corticosterone (A) and ACTH (B) were measured by standard ELISA. Data are presented 
as mean ± SEM; statistical significance was determined using a 2-way ANOVA followed 
by Tukey’s post-hoc test (n = 3–5; *P < 0.05, **P < 0.01, ***P < 0.001). 
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Figure 2.2: Effects of prenatal BPA exposure on plasma corticosterone and ACTH 
levels. 
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2.3.3 Effects of prenatal BPA exposure on perilipin protein levels 
To determine if prenatal exposure to BPA altered substrate availability for adrenal 
steroidogenesis, adrenal levels of perilipin, a surrogate for cholesterol content 13, were 
measured using western blot analysis. The level of perilipin protein was similar between 
control and prenatally BPA-exposed mice in both sexes (Figure 2.3). 
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Figure 2.3: Effects of prenatal BPA exposure on perilipin protein levels in adrenal 
glands. 
Pregnant mice were fed a control diet (phytoestrogen free food pellets) or the control diet 
supplemented with 25 mg BPA/kg food pellets from E7.5 to birth. At eight weeks of age, 
offspring were sacrificed, and adrenal glands were collected. Levels of perilipin protein 
in adrenal gland tissue homogenates were determined separately in males (A & C) and 
females (B & D) by western blot analysis. Data are presented as mean ± SEM (n = 4). 
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2.3.4 Effects of prenatal BPA exposure on StAR and cyp11A1 
protein levels 
To study the effects of prenatal exposure to BPA on the rate-limiting steps of 
steroidogenesis, levels of StAR and cyp11A1 proteins were measured by western 
blotting. We found a significant increase in both StAR (P < 0.01) and cyp11A1 (P < 0.05) 
protein levels in prenatally BPA exposed female mice compared to controls (Figure 
2.4B, D & F). By contrast, no changes in either StAR or cyp11A1 protein were observed 
in male mice prenatally exposed to BPA when compared to control males (Figure 2.4A, 
C & E). 
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Figure 2.4: Effects of prenatal BPA exposure on StAR and Cyp11A1 protein levels. 
Pregnant mice were fed a control diet (phytoestrogen free food pellets) or the control diet 
supplemented with 25 mg BPA/kg food pellets from E7.5 to birth. At eight weeks of age, 
offspring were sacrificed, and adrenal glands were collected. Levels of StAR and 
cyp11A1 protein in adrenal gland tissue homogenates were determined separately in 
males (A, C & E) and females (B, D, & F) by western blot analysis. Data are presented as 
mean ± SEM (n = 4; *P < 0.05, **P < 0.01 vs. control). 
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2.3.5 Effects of prenatal BPA exposure on SF-1 protein levels 
To investigate the effects of prenatal exposure to BPA on the regulatory mechanisms of 
adrenal steroidogenesis, we examined the expression of steroidogenic factor-1 (SF-1), a 
key transcription factor involved in the regulation of StAR and cyp11A1. We found no 
significant changes in the level of SF-1 protein in either female or male mice prenatally 
exposed to BPA when compared to control mice of the same sex (Figure 2.5). 
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Figure 2.5: Effects of prenatal BPA exposure on SF-1 protein levels in adrenal 
glands. 
Pregnant mice were fed a control diet (phytoestrogen free food pellets) or the control diet 
supplemented with 25 mg BPA/kg food pellets from E7.5 to birth. At eight weeks of age, 
offspring were sacrificed, and adrenal glands were collected. Levels of SF-1 protein in 
adrenal gland tissue homogenates were determined separately in males (A & C) and 
females (B & D) by western blot analysis. Data are presented as mean ± SEM (n = 4). 
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2.4 Discussion 
In the present study, we demonstrate that prenatal exposure to BPA results in increased 
basal corticosterone levels independent of circulating ACTH levels in both male and 
female adult mouse offspring. Furthermore, we provide evidence indicating that BPA-
induced increases in basal corticosterone levels are likely a consequence of up-regulated 
adrenal steroidogenesis in female mice while the mechanisms behind the BPA-induced 
increase in corticosterone levels in males are unknown. Thus, our present findings 
provide novel insight into the long-term and sex-specific effects of developmental BPA 
exposure on adrenal steroidogenesis. 
 
The dose of BPA used in this study (25 mg BPA/kg diet; equivalent to 5 mg BPA/kg 
body weight) was chosen based on our previous dose-response studies in which we found 
that prenatal exposure to this dose of BPA led to impaired fetal lung maturation without 
any effect on fetal body weight or litter size 14. This dose is also one tenth of the no 
observed adverse effect level (NOAEL) for rodents (50 mg/kg/day), as determined by the 
U.S. Environmental Protection Agency (IRIS 2012). Importantly, maternal 
concentrations of BPA in our mouse model were determined to be 1.7 ng/ml measured 
using gas chromatography–mass spectrometry (GC–MS) 14, which is at the lower end of 
the range of those reported in the serum of pregnant women in the US 15. 
 
As a first step in investigating the effects of prenatal BPA exposure on adrenal gland 
development and function, we sought to determine changes in adrenal gland weight. We 
found that the weight of adrenal glands was significantly increased in both male and 
female mice prenatally exposed to BPA when compared to offspring of control mice. 
Since BPA did not alter body weight, we observed a similar increase in the ratio of 
adrenal gland weight to body weight in prenatally BPA-exposed offspring in both sexes. 
This is in marked contrast to the findings of a previous study, which showed that 
maternal BPA exposure during pregnancy and lactation led to increases in both adrenal 
gland weight and the ratio of adrenal to body weight only in female but not male juvenile 
rats 8. Although the precise reasons for the discrepancy between the two studies are not 
clear, it is possible that differences in the dosage of BPA and the length of its exposure as 
well as the animal species and the offspring age (at which the study was conducted) are 
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important contributing factors. Increased adrenal weight can result in increased adrenal 
steroid output, which can be a result of increased output per adrenal cell and/or an 
increase in the number of adrenal cells. 
 
We then determined the functional significance of the BPA-induced increases in adrenal 
gland weight by examining changes in plasma levels of corticosterone, the principal 
glucocorticoid synthesized by the adrenal gland in rodents. We found that although 
prenatal exposure to BPA resulted in a significant increase in basal corticosterone levels 
in both male and female mice, this increase was greater in BPA exposed males compared 
to BPA females. This suggests that plasma corticosterone levels are more vulnerable to 
BPA exposure in utero in male than in female offspring. Previous studies reported sex-
dependent changes in plasma corticosterone resulting from developmental exposure to 
BPA. For example, one study showed that prandial administration of 40 µg BPA/kg body 
weight per day throughout pregnancy and lactation led to elevated plasma corticosterone 
levels in juvenile female and but not male rats 8,9. In another study, Zhou, et al. 10 also 
observed an increase in basal corticosterone in female juvenile rats exposed to 40 µg 
BPA/kg body weight per day throughout pregnancy and lactation; however male rats 
were not examined in that study. In contrast, Chen, et al. 11 reported an increase in 
corticosterone levels in adult male but not female rats as a result of daily subcutaneous 
administration of 2 µg BPA/kg body weight from gestation day 10 to lactation day 7. 
These discrepancies can be attributed to differences in the study design, including the 
dosage, the timing, the duration, and the mode of BPA administration as well as the age 
at which corticosterone levels were measured. Consistent with previous studies, there 
were no differences in basal corticosterone levels between control male and female adult 
mice 16-18. It is interesting to note that basal corticosterone levels were slightly higher in 
both males and females in our study when compared to those published previously 19-21, 
which may be attributed to differences in the time of the day when blood samples were 
collected, because corticosterone is known to be released in a circadian fashion 22,23. 
Furthermore, the presence of varying degrees of potential stressors in the animal housing 
environment, such as noise, human traffic and lighting conditions, may also be a 
contributing factor 24-26. 
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Given that elevated circulating corticosterone levels are commonly associated with 
enhanced ACTH release from the anterior pituitary 27, we measured plasma ACTH levels 
and found that they were not altered in either female or male offspring following prenatal 
BPA exposure. This suggested that the BPA-induced increases in basal plasma 
corticosterone levels are independent of pituitary ACTH, and likely the result of a direct 
effect of BPA on the adrenal gland. Our present findings are in marked contrast with 
those reported previously showing a concomitant increase in plasma levels of 
corticosterone and ACTH in adult male rats 11 and juvenile female rats following 
perinatal exposure to BPA 10. As discussed above, differences in the timing, dosage and 
duration of BPA exposure likely accounted for the contrasting findings between these 
studies. 
 
Our conclusion of BPA exerting a direct effect on the adrenal gland is supported by 
previously published in vitro evidence showing that BPA inhibited cortisol and 
corticosterone secretion in human adenocarcinoma H295R cells, by inhibiting cyp17A1 
(17,20 lyase) 28. Furthermore, BPA reduced the mRNA levels of StAR and cyp11A1, the 
two rate-limiting factors in the de novo steroidogenesis, in cultured mouse ovarian 
follicles 29,30, while another study reported increased mRNA levels in rat ovarian theca-
interstitial (T-I) cells and granulosa cells following exposure to BPA 31. Furthermore, 
BPA has been shown to alter mRNA levels of other steroidogenic P450 enzymes, such as 
3β-HSD and 17β-HSD in rat testis 32. In addition, BPA inhibited the activities of 3β-
HSD, CYP17A1 and 17β-HSD3 in both human and rat testis microsomes 33. However, to 
date, changes in the expression of StAR and cyp11A1, or any other proteins/enzymes 
involved in steroidogenesis, in the adrenal gland following BPA exposure in vivo have 
not been examined. 
 
As a first step in examining the effects of prenatal exposure to BPA on steroidogenesis in 
the adrenal gland, we sought changes in substrate availability by determining and 
comparing levels of perilipin protein between control and BPA exposed offspring. 
Perilipin is a protective coating protein surrounding the periphery of lipid droplets, which 
are stored in the adrenal gland and are associated with cholesterol ester droplets 13,34. We 
found that perilipin protein content was not different between control and BPA exposed 
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mice in either sex, suggesting that cholesterol content, and by inference the substrate 
availability for steroidogenesis, is not altered in adult mouse offspring prenatally exposed 
to BPA. This is similar to the findings of a previous in vitro study, which showed that 
BPA had no effect on perilipin levels in human hepatocyte cells 35. To the best of our 
knowledge, this is the first study to examine changes in perilipin expression following 
BPA exposure in vivo. 
 
We then examined changes in StAR and cyp11A1, the two rate-limiting steps in 
steroidogenesis. We found that adrenal protein levels of both StAR and cyp11A1 were 
elevated in female but not male mice, suggesting that the BPA-induced increases in 
corticosterone levels in our female offspring are likely the result of an enhanced adrenal 
steroidogenesis. Importantly, these findings demonstrate that although prenatal exposure 
to BPA alters basal plasma corticosterone levels in both male and female offspring, its 
effects on adrenal steroidogenesis are sex-specific. A similar sex-dependent effect was 
reported by Xi, et al. 36, who showed that developmental exposure to BPA led to 
decreased expression of StAR and cyp11A1 in the testes, whereas no changes in StAR 
and an increase in cyp11A1 were detected in the ovaries. However, the lack of a 
corresponding increase in StAR and cyp11A1 in the adrenal gland of the male offspring 
begs the question of the reasons behind increased corticosterone levels in these animals. 
Potential mechanisms/reasons may include changes in one or more of the steroidogenic 
enzymes downstream of cyp11A1. Obviously, future studies will be required to address 
this issue. 
 
Given that steroidogenic factor-1 (SF-1) is a key transcription factor responsible for the 
induction of StAR and cyp11A1 as well as other steroidogenic enzymes  37,38, we 
determined if changes in the expression of this transcription factor are responsible for our 
observed increases in levels of StAR and cyp11A1 proteins in the adrenal gland of BPA-
exposed female offspring. We found that adrenal levels of SF-1 protein were similar 
between control and BPA-exposed mice in both males and females. This suggested that 
other transcription factors, such as C/EBPs, Sp1, and DAX1 39,40, may be involved in up-
regulating StAR and cyp11A1 in the adrenal gland of our BPA-exposed female offspring. 
Alternatively, BPA-induced phosphorylation of SF-1 could account for the increased 
 91 
level of StAR and cyp11A1 protein, since phosphorylation of SF-1 at the StAR promoter 
is required to increase expression of StAR 41,42. Obviously, future studies will be required 
to examine these possibilities. It is interesting to note that BPA exposure resulted in 
decreased expression of SF-1 in cultured human granulosa cells 43. 
2.5 Conclusion 
In conclusion, the present study demonstrates that prenatal exposure to BPA disrupts 
corticosterone homeostasis in the circulation without altering plasma ACTH levels in 
both male and female adult mouse offspring. We also provide evidence that BPA disrupts 
steroidogenesis independent of SF-1 in a sex-specific manner. Thus, our present findings 
provide novel insight into the dynamic effects of developmental exposure to BPA on the 
pituitary-adrenal axis development and function. 
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3 BISPHENOL A INDUCES STEROIDOGENIC ACUTE 
REGULATORY PROTEIN (StAR) EXPRESSION VIA 
AN UNKNOWN MECHANISM INDEPENDENT OF 
TRANSCRIPTION, TRANSLATION AND PROTEIN 
HALF-LIFE IN HUMAN ADRENAL CORTICAL CELLS1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 The material in this chapter is based on a manuscript submitted to Steroids: Medwid S, 
Guan H, Yang K. Bisphenol A induces steroidogenic acute regulatory protein (StAR) 
expression via an unknown mechanism independent of transcription, translation and 
protein half-life in human adrenal cortical cells (2017). 
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3.1 Introduction  
In Chapter 2, I demonstrated that prenatal BPA exposure increased StAR protein 
expression in adult female offspring. Given that StAR is the rate-limiting step in adrenal 
steroidogenesis, in the following chapter, I sought to determine the molecular 
mechanisms underlying BPA-induced StAR expression using an in vitro cell model 
system 
 
Bisphenol A (BPA) is a widespread endocrine disrupting chemical, and a source of major 
health concerns. BPA is commonly used in polycarbonate plastics and epoxy resins, such 
as plastic containers and the inner-lining of food cans 1-5. BPA is present in human saliva, 
urine, and plasma. More concerning is the presence of BPA in placenta, cord blood, 
amniotic fluid and breast milk 6-9, raising serious concerns about exposure to BPA in 
utero and during critical periods of postnatal development 10. Indeed, numerous human 
epidemiological studies have demonstrated an association between gestational exposure 
to BPA and adverse health outcomes including pregnancy complications, male genital 
abnormalities, childhood obesity, childhood asthma and altered neurological development 
in children and adults 11-13.  
 
We recently showed that prenatal BPA exposure led to altered adrenal gland development 
and function in adult mouse offspring 14. Specifically, plasma levels of corticosterone 
were elevated concomitant with increased adrenal levels of steroidogenic acute regulatory 
protein (StAR), the rate-limiting step in steroidogenesis, in adult female offspring 14. 
StAR is responsible for the transport of free cholesterol from the outer mitochondrial 
membrane (OMM) to the inner mitochondria membrane (IMM),  the first and the rate-
limiting step in steroidogenesis 15. BPA is known to alter StAR mRNA and protein levels 
in various reproductive tissues, and these effects appear to be species-, sex-, dose- and 
exposure time-specific 16-27. However, the molecular mechanisms underlying the effects 
of BPA on steroidogenesis, and particularly StAR expression are largely unknown. 
Therefore, the present study was designed to address this important question using a 
human adrenal cortical cell line as an in vitro model system.  
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3.2 Methods 
3.2.1 Reagents 
Bisphenol A was purchased from Sigma-Aldrich Canada Ltd. (>99% purity; CAS 80-05- 
7; Oakville, ON) and dissolved in ethanol to prepare a 10mM stock solution, and stored 
at -20°C. ICI 182, 760 (ICI) was purchased from Tocris (cat. no. 1047) and dissolved in 
DMSO to prepare a 100mM stock, and stored at -20°C. 4,4',4''-(4-Propyl-[1H]-pyrazole-
1,3,5-triyl)trisphenol) (PPT) and 2,3-bis(4-Hydroxyphenyl)-propionitrile (DPN) were 
purchased from Tocris (cat. no. 1426 and 1494, respectively) and dissolved in ethanol to 
a concentration of 5 mM and 100 mM, respectively, and stored at -20°C. Cycloheximide 
(CHX) was purchased from Sigma (C-0934) and dissolved in ethanol to prepare a 100 
mM stock and stored at -20°C. 
3.2.2 Cell Culture 
The adrenocortical human cell line NCI-H295 cell line was derived from an adrenal 
tumor of a 48-year-old female and was first described by Gazdar et al. 28. The NCI-H295 
cell line expresses all steroidogenic enzymes present in the human fetal adrenal glands 
and is an established model to study adrenal steroidogenesis 29. The subline, NCI-H295A, 
was further derived and characterized from the H295R cell line, and is currently the best 
available model of human fetal adrenal gland cells 30. H295A cells (generously provided 
by Dr. Walter L. Miller) were cultured in RPMI 1640 media (Invitrogen) with 2% fetal 
bovine serum (FBS; Sigma), 0.1% insulin-transferrin-selenium supplement (Sigma 
I18884) and 100IU penicillin and 100µg/mL streptomycin (Invitrogen) at 37°C (5% 
CO2). Growth medium was replaced every other day.  
3.2.3 Western Blot Analysis 
 Levels of various proteins were analyzed using standard western blot analysis, as 
previously described 31. Briefly, cells were lysed in SDS gel loading buffer (50 mM Tris-
HCL, pH 6.8, 2% wt/vol SDS, 10% vol/vol glycerol, 100 mM DTT and 0.1% wt/vol 
bromophenol blue) to be loaded in a standard SDS-PAGE gel. Protein was then 
transferred to a PVDF transfer membrane (Amersham Hybond-P, cat. no. RPN303F, GE 
Healthcare Lifesciences, Baie D'Urfe, QC), and blocked overnight with 5% milk in TTBS 
(0.1% vol/vol Tween-20 in TBS). Membranes were then probed with primary antibodies 
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for 1-2 hours at room temperature (Table 3.1). Washing was done with TTBS, 3×10 
minutes before labeling with horseradish peroxidase-labeled secondary antibody (Table 
3.1) for 1 hour at room temperature. After 3×10 minute TTBS washes, proteins were 
detected using ECL and visualized using chemiluminescence (cat. no. WBLUR0500, 
Luminata Crescendo, Western HRP Substrate; Millipore, Etobicoke, ON) and captured 
on the VersaDoc Imaging System (BioRad). Densitometry was performed using Image 
Lab Software, comparing levels of proteins expressed as percent of controls.  
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Table 3.1: Primary and secondary antibodies used for western blotting. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Antibody Company Catalog Number Dilution Used 
StAR Santa Cruz Sc-25806 1:4000 
GAPDH Cell Signaling 14C10 1:10000 
Cyp11A1 Bioss Bs-3608R 1:200 
3β-HSD Santa Cruz Sc-30820 1:500 
ERα Santa Cruz Sc-543 1:500 
ERβ Santa Cruz Sc-8974 1:1000 
SF-1 Abcam Ab168380 1:1000 
C/EBPβ Snata Cruz Sc-150 1:500 
Sp1 Millipore 17-601 1:8000 
AKAP149 Santa Cruz Sc-377450 1:100 
β-tubulin Imgenex IMG-5810A 1:1000 
Anti-Rabbit R&D systems HAF008 1:3000 
Anti-goat Millipore AP180P 1:8000 
Anti-mouse  BIO RAD 170-6516 1:7500 
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3.2.4 Real time quantitative RT-PCR 
The relative abundance of various mRNAs was determined by a two-step real time 
quantitative RT-PCR (qRT-PCR), as described previously 32, with the following 
modifications. Briefly, total RNA was extracted from cells using RNeasy Mini Kit 
(Qiagen Inc., Mississauga, ON) coupled with on-column DNase digestion with the 
RNase-free DNase Set (Qiagen) according to the manufacturer’s instructions. One 
microgram of total RNA was reverse-transcribed in a total volume of 20 µl using the 
High Capacity cDNA Archive Kit (Applied Biosystems, Forest City, CA) following the 
manufacturer’s instructions. For every RT reaction set, one RNA sample was set up 
without reverse-transcriptase enzyme to provide a negative control. Gene transcript levels 
of GAPDH (housekeeping gene whose expression level was found to be stable across 
all treatment groups), and StAR were quantified separately by pre-designed and validated 
TaqMan® Gene Expression Assays (Applied Biosystems; GAPDH Hs02758991_g1; 
StAR Hs00986559_g1) following the manufacturer’s instructions. Briefly, gene 
expression assays were performed with the TaqMan® Gene Expression Master Mix 
(Applied Biosystems P/N #4369016) and the universal thermal cycling condition (2 min 
at 50 °C and 10 min at 95 °C, followed by 40 cycles of 15 s at 95 °C and 1 min at 60 °C) 
on the ViiA™ 7 Real-Time PCR System (Applied Biosystems). 
 
The relative amount of StAR and GAPDH mRNA was quantified by the comparative 
CT method (also known as ΔΔ CT method) using the Applied Biosystems relative 
quantitation and analysis software according to the manufacturer’s instructions. The 
amount of StAR mRNA was normalized to GAPDH (housekeeping gene) for each 
treatment group. StAR mRNA in BPA treatment is expressed relative to the amount of 
transcript present in the control. 
3.2.5 Statistical Analysis 
Results are presented as group means ± SEM for each treatment group, as indicated. 
Control and BPA groups were compared using a Student’s t-test or a one-way ANOVA, 
followed by a Tukey’s post hoc; statistical significance was set at P<0.05. Statistical 
analysis was performed using statistical software PRISM 1992-2008 GraphPAD 
Software. 
 102 
3.3 Results 
3.3.1 Concentration-dependent effects of BPA on StAR protein 
expression 
To validate this in vitro model system, we determined the effects of various 
concentrations of BPA on StAR protein levels in H295A cells. We found that treatment 
with increasing concentrations of BPA (1-1000 nM) for 48 h resulted in a concentration-
dependent increase in StAR protein levels (Figure 3.1). 
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Figure 3.1: Concentration-dependent effects of BPA on StAR protein expression. 
H295A cells were treated with various concentrations of BPA (1 – 10000 nM) for 48 h. 
At the end of treatment, levels of StAR protein were determined by western blotting. 
Data are presented as means ± SEM (**P<0.01, ***P<0.001; n=4 independent 
experiments). 
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3.3.2 Effects of BPA on selected key steroidogenic enzymes  
To assess the effects of BPA on adrenal steroidogenesis, protein levels of the two key 
steroidogenic enzymes, Cyp11A1 and 3β-HSD, were measured following treatment with 
10 nM BPA. We showed that protein levels of both Cyp11A1 and 3β-HSD were not 
different between cells treated with and without BPA (Figure 3.2A & B).  
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Figure 3.2: Effects of BPA on selected key steroidogenic enzymes. 
H295A cells were treated with 10 nM of BPA for 48 h. At the end of treatment, protein 
levels of Cyp11A1 (A) and 3b-HSD (B) were measured by western blotting. Data are 
presented as means ± SEM (n=4 independent experiments). 
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3.3.3 Effects of BPA on ERα and β protein expression  
To determine the effects of BPA on ER expression, protein levels of ERα and ERβ were 
assessed following BPA treatment. We found that neither ERα (Figure 3.3A) nor ERβ 
(Figure 3.3B) protein levels were altered by BPA.  
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Figure 3.3: Effects of BPA on ERα and β protein expression. 
H295A cells were treated with 10 nM of BPA for 48 h. At the end of treatment, protein 
levels of ERa (A), and ERb (B) were measured by western blotting. Data are presented 
as means ± SEM (n=4 independent experiments). 
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3.3.4 Effects of ER agonists and antagonist on StAR protein 
expression 
BPA has been shown to activate both ERα and ERβ 33-35. As a first step in determining if 
ER is involved in mediating the effects of BPA on StAR expression, we assessed changes 
in StAR expression following treatment with the ERα selective agonist PPT and the ERβ 
selective agonist DPN, respectively (Figure 3.4A). We found that both PPT and DPN 
increased StAR protein levels. We then examined the effects of the ER antagonist ICI 
182, 780 (ICI) on BPA-induced expression of StAR. We showed that ICI completely 
prevented BPA-induced increases in levels of StAR protein (Figure 3.4B).  
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Figure 3.4: Effects of ER agonists and antagonist on StAR protein expression. 
H295A cells were treated with 10 nM PPT, 10 nM DPN, 10 nM BPA, 100 nM ICI 
182,780 (ICI), or BPA plus ICI for 48 h. At the end of treatment, levels of StAR protein 
were measured by western blotting (A&B). Data are presented as means ± SEM 
(*P<0.05, **P<0.01; n=5 independent experiments). 
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3.3.5 Effects of BPA on key StAR transcription factors and StAR 
mRNA levels  
To explore the molecular mechanisms underlying BPA-induced StAR protein expression, 
we determined the effects of BPA on the expression of key StAR transcription factors 
15,36 and StAR mRNA. Although BPA did not alter SF-1 protein levels (Figure 3.5A), it 
increased protein levels of C/EBPβ (Figure 3.5B) and Sp1 (Figure 3.5C). Interestingly, 
BPA had no effect on StAR mRNA (Figure 3.5D). 
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Figure 3.5: Effects of BPA on key StAR transcription factors and StAR mRNA 
levels. 
H295A cells were treated with 10 nM of BPA for 48 h. At the end of treatment, protein 
levels of SF-1 (A), C/EBPβ (B) and Sp-1 (C) as well as levels of StAR mRNA (D) levels 
were measured by western blotting and qRT-PCR, respectively. Data are presented as 
means ± SEM (**P<0.01; n=4 independent experiments).  
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3.3.6 Effects of BPA on key StAR translation protein and StAR 
pre-protein 
We then investigated the possibility that BPA may influence the translation of StAR 
protein by examining changes in the key kinase involved in recruiting StAR mRNA and 
translating it, namely A-Kinase anchoring protein (AKAP) 149 37,38 as well as the 37-kDa 
StAR pre-protein 39. Treatment with BPA did not alter levels of either AKAP149 protein 
(Figure 3.6A) or 37-kDa StAR pre-protein (Figure 3.6B). 
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Figure 3.6: Effects of BPA on key StAR translation protein and StAR pre-protein. 
H295A cells were treated with 10 nM of BPA for 48 h. At the end of treatment, levels of 
AKAP149 protein (A) and 37-kDa StAR pre-protein (B) were measured by western 
blotting. Data are presented as means ± SEM (n=4 independent experiments). 
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3.3.7 Effects of BPA on half-life of StAR protein 
To determine if BPA alters the half-life of StAR protein, cells were treated with BPA for 
48 h, followed by co-treatment with the translation inhibitor cycloheximide (CHX) for 2 
and 4 hours prior to harvesting for StAR protein measurement. We found that BPA did 
not affect the half-life of StAR protein (Control=3.1 h; BPA=3.0 h; Figure 3.7).  
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Figure 3.7: Effects of BPA on half-life of StAR protein. 
H295A cells were treated with 10 nM of BPA for 48 h, and then 10 µM cycloheximide 
(CHX) was added for 2 h and 4 h prior to harvest. StAR protein levels were measured by 
western blotting, and its half-life determined by standard method. Data are presented as 
means ± SEM (n=4 independent experiments). 
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3.4 Discussion 
Adrenal steroidogenesis and most notably glucocorticoid production is critically 
controlled by the rate-limiting protein StAR 15,40. We recently demonstrated that prenatal 
exposure to BPA resulted in altered adrenal development and function leading to 
increased plasma corticosterone levels in adult mouse offspring 14. Furthermore, the 
increased plasma corticosterone levels were concomitant with elevated adrenal levels of 
StAR protein in female but not male adult offspring 14. This gender-specific changes in 
StAR expression is intriguing and begs the question of the molecular mechanisms that 
underlie BPA-induced adrenal StAR expression in female offspring. Thus, the present 
study was designed to address this important question using the H295A cell line, which is 
currently the best available in vitro model of human fetal adrenal cortical cells. Using this 
model, we have provided evidence indicating that BPA induces StAR protein expression 
via an ER-mediated novel molecular mechanism that does not appear to involve StAR 
gene transcription, translation or protein half-life.  
 
The concentration range of BPA (1-10000 nM) used in the present study was consistent 
with that used previously in vitro 41, and was lower than what was previously shown to 
alter the steroidogenic pathway in non-adrenal cells 16-19. Importantly, the 10 nM BPA 
concentration (equivalent to 2.28 ng/ml) used throughout the present study is well within 
the range previously reported in urine (0.16-43.42 ng/ml) 42 and plasma (0.5-22.3 ng/ml) 
43 of pregnant women.  
 
Since we previously demonstrated that prenatal BPA exposure led to increased StAR 
protein levels in adrenal glands of female offspring 14, we sought first to validate our in 
vitro model system. Indeed, we found that BPA increased StAR protein levels in a 
concentration-dependent manner in H295A adrenal cortical cells. Previously, numerous 
studies have examined the effects of BPA treatment on StAR protein levels in 
reproductive organs with varying effects 22-27. In vivo studies demonstrated decreased 
StAR protein levels in the testes and ovaries of rodents after acute BPA exposure 22-25,27. 
In contrast, Qiu et al. 26 observed increased StAR protein levels in the testes of male rats 
after chronic BPA treatment. Thus, the effects of BPA exposure on StAR protein appear 
to be organ-, tissue- and dose-specific. However, to date no studies have been reported to 
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examine the molecular mechanisms by which BPA induced StAR expression in any 
steroidogenic tissues or cells.  
 
BPA has been shown to affect other key steroidogenic enzymes involved in adrenal 
glucocorticoid production, including cyp11A1 and 3β-HSD 14,44,45. We also examined 
changes in these key enzymes, and found that protein levels of both cyp11A1 and 3β-
HSD were not altered by BPA treatment. It is interesting to note that we previously 
reported that prenatal BPA exposure led to increased adrenal levels of cyp11A1 protein 
in female but not male adult mouse offspring 14. Furthermore, Lan et al. 45 used the 
adrenal mouse cell line, Y1, as well as male mice treated with acute doses of BPA, and 
demonstrated an increase in adrenal cyp11A1 protein levels. However, in H295R adrenal 
cortical cells, only very high concentrations of BPA (10 µM) were shown to decrease 
mRNA levels of cyp11A1 and 3β-HSD 44. Thus, these discrepancies in BPA-induced 
changes in cyp11A1 and 3β-HSD may be explained by differences in cell lines, treatment 
regime, BPA doses/concentrations and exposure times. Taken together, these findings 
suggest that BPA affects adrenal steroidogenesis primarily through altered StAR protein 
expression.  
 
BPA is a known agonist for ERβ, and has dual agonistic and antagonistic actions for 
ERα, with a higher binding affinity to ERβ than to ERα 34,35. Additionally, human H295R 
adrenal cortical cells have been shown to express both ERα and ERβ, with the latter 
being the dominant receptor present 46. Therefore, we first examined the effects of BPA 
on ERα and ERβ protein expression. We found that levels of both ERα and ERβ protein 
were not changed after 48 hours of BPA treatment. ERα null mice showed increased 
StAR levels in fetal and adult testes 47,48. Additionally, male transgenic mice expressing 
human aromatase, resulting in higher than normal levels of estrogen, had decreased StAR 
levels 47,48.However, whether a similar phenotype is present in the adrenal glands is 
unknown. We then examined the effects of ERα- and ERβ-specific agonists, PPT and 
DPN, on StAR protein. We found that both PPT and DPN increased StAR protein levels, 
indicating that both ERα and ERb are involved in regulating StAR expression. To 
determine if BPA signals through ER to increase StAR expression, cells were treated 
with BPA in the presence and absence of the ER antagonist ICI. We found that ICI 
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abrogated the stimulatory effects of BPA on StAR protein levels. Taken together, these 
results suggest that BPA induces StAR protein expression via ERα and/or ERb in adrenal 
cortical cells.  
 
StAR is thought to be largely regulated transcriptionally, with numerous transcription 
factors binding to the StAR promoter 15,37,40,49. SF-1 is a master regulator of adrenal 
steroidogenesis, since SF-1 null mice exhibited diminished basal levels of StAR 15,37,40,50. 
Other key transcription factors involved in StAR regulation include C/EBPβ and Sp1 
15,37,40. Therefore, we investigated the effects of BPA on these three key transcription 
factors. We found that protein levels of SF-1 were unchanged by BPA, which is 
consistent with what we and others have previously demonstrated in experimental animal 
models 14,51. In contrast, we found protein levels of C/EBPβ and Sp1 were increased after 
48 hours of BPA treatment. Increased levels of C/EBPβ were also observed in 3T3-L1 
pre-adipocyte cells after BPA treatment 52. C/EBPβ expression was decreased in livers of 
male, but not female, offspring after prenatal BPA exposure 53. Previously, Sp1 was 
shown to be decreased in resorbed embryos but unchanged in viable embryos 54. Taken 
together, these findings suggest that BPA alters the expression of specific transcription 
factors known to regulate StAR transcription.  
 
As a first step in determining if BPA affects StAR transcription, we measured StAR 
mRNA levels. StAR mRNA was found to be unchanged after 48 hours of BPA treatment. 
This is consistent with a previous study in H295R adrenal cortical cells, which showed 
that low concentrations of BPA (0.1-1 µM) did not affect StAR mRNA levels, while 
higher concentrations of BPA (10 µM) decreased StAR mRNA 44. Other studies in 
reproductive tissues also demonstrated no significant changes in StAR mRNA after BPA 
treatment 20,21; however, StAR protein levels were not measured in those studies. In 
contrast, numerous studies in reproductive cells showed altered StAR mRNA levels, but 
results varied greatly in direction and magnitude of change 16-19. Interestingly, StAR 
protein levels have been shown to be altered, independent of changes in StAR mRNA, 
after exposure to oxysterols 55, pesticides 56, endotoxins 57 and prostaglandins 58; 
however, the mechanisms behind these effects were not examined. Collectively, these 
findings suggest that BPA regulate StAR primarily at post-transcriptional levels. 
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Recent evidence has pointed to a potential post-transcriptional regulation of StAR  37,40. 
One potential player is AKAP149, a mitochondrial anchoring protein, which recruits 
StAR mRNA to the OMM 37,38. AKAP149 at the OMM promotes the translation of StAR 
by binding the 3’ untranslated region of StAR mRNA to the K homology (KH) RNA-
binding motif 37,38,59. Therefore, we investigated the effects of BPA on AKAP149 protein 
levels, which we found to be unaltered after 48 hours of BPA treatment. However, we 
recognized that the activity of AKAP121/149 as well as protein levels and the activity of 
other key translational regulators were not examined in this study. StAR mRNA is 
translated into a 37-kDa pre-protein at the OMM 37,60. Thus, to ascertain the effects of 
BPA on StAR translation, we determined the level of the 37-kDa StAR pre-protein. We 
did not observe any changes in the 37-kDa StAR pre-protein levels after treatment for 48 
hours with BPA. Taken together, these results suggest that BPA does not affect the 
translation of StAR protein in adrenal cortical cells.  
 
To further investigate the molecular mechanisms underlying BPA-induced StAR protein 
expression, we determined the effects of BPA on StAR protein degradation. The 
degradation of the mature StAR protein occurs in the mitochondrial matrix by the two 
proteases, LON and AG132, as well as one or more unknown mitochondrial proteases 
61,62. As an indicator of protein degradation, the half-life of 30-kDa StAR protein was 
determined following treatment with BPA. No differences in the half-life of StAR protein 
were observed between control and BPA-treated cells. Taken together, these results 
indicate that BPA does not alter the degradation of StAR protein in H295A cells.  
 
Collectively, the present findings suggest that BPA does not regulate StAR protein levels 
through changes in transcription, translation or degradation. However, the regulation of 
StAR is extremely complex and is not yet fully understood 37,49,63. Thus, BPA may be 
acting through an unknown mechanism to modulate StAR expression, and obviously 
future studies will be required to examine this possibility. Additionally, due to the short 
half-life of both StAR pre- and mature protein 64, transcription and translation markers 
were only examined at 48 hours, however it is possible that changes in mRNA or 37-kDa 
StAR pre-protein could happen at earlier time points. Furthermore, we did not examine 
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the effects of BPA on the cleavage of StAR or its transportation from the OMM to the 
IMM. However, since we found no changes in the levels of 37-kDa StAR pre-protein, it 
is unlikely that BPA affects either of these two steps. Furthermore, this study did not 
measure the 32-kDa isoform of StAR protein, which, if changed, may provide a potential 
explanation for BPA-induced changes in mature StAR protein levels 60,64.  
 
In conclusion, the present study provides strong evidence that BPA signals through ERa 
and/or ERb to increase StAR protein levels in H295A cells via an unknown mechanism 
independent of StAR gene transcription, translation and protein half-life.  
3.5 References  
1 Vandenberg, L. N., Maffini, M. V., Sonnenschein, C., Rubin, B. S. & Soto, A. M. 
Bisphenol-A and the great divide: a review of controversies in the field of 
endocrine disruption. Endocrine reviews 30, 75-95, doi:10.1210/er.2008-0021 
(2009). 
2 Vandenberg, L. N. et al. Urinary, circulating, and tissue biomonitoring studies 
indicate widespread exposure to bisphenol A. Ciencia & saude coletiva 17, 407-
434 (2012). 
3 Richter, C. A. et al. In vivo effects of bisphenol A in laboratory rodent studies. 
Reproductive toxicology (Elmsford, N.Y.) 24, 199-224, 
doi:10.1016/j.reprotox.2007.06.004 (2007). 
4 Wetherill, Y. B. et al. In vitro molecular mechanisms of bisphenol A action. 
Reproductive toxicology (Elmsford, N.Y.) 24, 178-198, 
doi:10.1016/j.reprotox.2007.05.010 (2007). 
5 Rubin, B. S. Bisphenol A: an endocrine disruptor with widespread exposure and 
multiple effects. The Journal of steroid biochemistry and molecular biology 127, 
27-34, doi:10.1016/j.jsbmb.2011.05.002 (2011). 
6 Engel, S. M., Levy, B., Liu, Z., Kaplan, D. & Wolff, M. S. Xenobiotic phenols in 
early pregnancy amniotic fluid. Reproductive toxicology (Elmsford, N.Y.) 21, 110-
112, doi:10.1016/j.reprotox.2005.07.007 (2006). 
7 Ikezuki, Y., Tsutsumi, O., Takai, Y., Kamei, Y. & Taketani, Y. Determination of 
bisphenol A concentrations in human biological fluids reveals significant early 
prenatal exposure. Human reproduction (Oxford, England) 17, 2839-2841 (2002). 
8 Schonfelder, G. et al. Parent bisphenol A accumulation in the human maternal-
fetal-placental unit. Environmental health perspectives 110, A703-707 (2002). 
 121 
9 Yamada, H. et al. Maternal serum and amniotic fluid bisphenol A concentrations 
in the early second trimester. Reproductive toxicology (Elmsford, N.Y.) 16, 735-
739 (2002). 
10 Golub, M. S. et al. Bisphenol A: developmental toxicity from early prenatal 
exposure. Birth defects research. Part B, Developmental and reproductive 
toxicology 89, 441-466, doi:10.1002/bdrb.20275 (2010). 
11 Rochester, J. R. Bisphenol A and human health: a review of the literature. 
Reproductive toxicology (Elmsford, N.Y.) 42, 132-155, 
doi:10.1016/j.reprotox.2013.08.008 (2013). 
12 Mustieles, V., Perez-Lobato, R., Olea, N. & Fernandez, M. F. Bisphenol A: 
Human exposure and neurobehavior. Neurotoxicology 49, 174-184, 
doi:10.1016/j.neuro.2015.06.002 (2015). 
13 Veiga-Lopez, A. et al. Impact of gestational bisphenol A on oxidative stress and 
free fatty acids: Human association and interspecies animal testing studies. 
Endocrinology 156, 911-922, doi:10.1210/en.2014-1863 (2015). 
14 Medwid, S., Guan, H. & Yang, K. Prenatal exposure to bisphenol A disrupts 
adrenal steroidogenesis in adult mouse offspring. Environmental toxicology and 
pharmacology 43, 203-208, doi:10.1016/j.etap.2016.03.014 (2016). 
15 Reinhart, A. J., Williams, S. C. & Stocco, D. M. Transcriptional regulation of the 
StAR gene. Molecular and cellular endocrinology 151, 161-169 (1999). 
16 Peretz, J., Gupta, R. K., Singh, J., Hernandez-Ochoa, I. & Flaws, J. A. Bisphenol 
A impairs follicle growth, inhibits steroidogenesis, and downregulates rate-
limiting enzymes in the estradiol biosynthesis pathway. Toxicological sciences : 
an official journal of the Society of Toxicology 119, 209-217, 
doi:10.1093/toxsci/kfq319 (2011). 
17 Peretz, J. & Flaws, J. A. Bisphenol A down-regulates rate-limiting Cyp11a1 to 
acutely inhibit steroidogenesis in cultured mouse antral follicles. Toxicology and 
applied pharmacology 271, 249-256, doi:10.1016/j.taap.2013.04.028 (2013). 
18 Peretz, J., Neese, S. L. & Flaws, J. A. Mouse strain does not influence the overall 
effects of bisphenol a-induced toxicity in adult antral follicles. Biology of 
reproduction 89, 108, doi:10.1095/biolreprod.113.111864 (2013). 
19 Zhou, W., Liu, J., Liao, L., Han, S. & Liu, J. Effect of bisphenol A on steroid 
hormone production in rat ovarian theca-interstitial and granulosa cells. 
Molecular and cellular endocrinology 283, 12-18, doi:10.1016/j.mce.2007.10.010 
(2008). 
20 Mansur, A. et al. Does BPA alter steroid hormone synthesis in human granulosa 
cells in vitro? Human reproduction (Oxford, England) 31, 1562-1569, 
doi:10.1093/humrep/dew088 (2016). 
 122 
21 Savchuk, I., Soder, O. & Svechnikov, K. Mouse leydig cells with different 
androgen production potential are resistant to estrogenic stimuli but responsive to 
bisphenol a which attenuates testosterone metabolism. PloS one 8, e71722, 
doi:10.1371/journal.pone.0071722 (2013). 
22 Chouhan, S. et al. Increase in the expression of inducible nitric oxide synthase on 
exposure to bisphenol A: A possible cause for decline in steroidogenesis in male 
mice. Environmental toxicology and pharmacology 39, 405-416, 
doi:10.1016/j.etap.2014.09.014 (2015). 
23 Nakamura, D. et al. Bisphenol A may cause testosterone reduction by adversely 
affecting both testis and pituitary systems similar to estradiol. Toxicology letters 
194, 16-25, doi:10.1016/j.toxlet.2010.02.002 (2010). 
24 D'Cruz, S. C., Jubendradass, R., Jayakanthan, M., Rani, S. J. & Mathur, P. P. 
Bisphenol A impairs insulin signaling and glucose homeostasis and decreases 
steroidogenesis in rat testis: an in vivo and in silico study. Food and chemical 
toxicology : an international journal published for the British Industrial 
Biological Research Association 50, 1124-1133, doi:10.1016/j.fct.2011.11.041 
(2012). 
25 Lee, S. G. et al. Bisphenol A exposure during adulthood causes augmentation of 
follicular atresia and luteal regression by decreasing 17beta-estradiol synthesis via 
downregulation of aromatase in rat ovary. Environmental health perspectives 121, 
663-669, doi:10.1289/ehp.1205823 (2013). 
26 Qiu, L. L. et al. Decreased androgen receptor expression may contribute to 
spermatogenesis failure in rats exposed to low concentration of bisphenol A. 
Toxicology letters 219, 116-124, doi:10.1016/j.toxlet.2013.03.011 (2013). 
27 Xi, W. et al. Effect of perinatal and postnatal bisphenol A exposure to the 
regulatory circuits at the hypothalamus-pituitary-gonadal axis of CD-1 mice. 
Reprod Toxicol 31, 409-417, doi:10.1016/j.reprotox.2010.12.002 (2011). 
28 Gazdar, A. F. et al. Establishment and characterization of a human adrenocortical 
carcinoma cell line that expresses multiple pathways of steroid biosynthesis. 
Cancer research 50, 5488-5496 (1990). 
29 Staels, B., Hum, D. W. & Miller, W. L. Regulation of steroidogenesis in NCI-
H295 cells: a cellular model of the human fetal adrenal. Molecular endocrinology 
(Baltimore, Md.) 7, 423-433, doi:10.1210/mend.7.3.8387159 (1993). 
30 Rodriguez, H., Hum, D. W., Staels, B. & Miller, W. L. Transcription of the 
human genes for cytochrome P450scc and P450c17 is regulated differently in 
human adrenal NCI-H295 cells than in mouse adrenal Y1 cells. The Journal of 
clinical endocrinology and metabolism 82, 365-371, doi:10.1210/jcem.82.2.3721 
(1997). 
 123 
31 Selvaratnam, J., Guan, H., Koropatnick, J. & Yang, K. Metallothionein-I- and -II-
deficient mice display increased susceptibility to cadmium-induced fetal growth 
restriction. American journal of physiology. Endocrinology and metabolism 305, 
E727-735, doi:10.1152/ajpendo.00157.2013 (2013). 
32 Rajakumar, C., Guan, H., Langlois, D., Cernea, M. & Yang, K. Bisphenol A 
disrupts gene expression in human placental trophoblast cells. Reproductive 
toxicology (Elmsford, N.Y.) 53, 39-44, doi:10.1016/j.reprotox.2015.03.001 (2015). 
33 Kuiper, G. G. et al. Comparison of the ligand binding specificity and transcript 
tissue distribution of estrogen receptors alpha and beta. Endocrinology 138, 863-
870, doi:10.1210/endo.138.3.4979 (1997). 
34 Alonso-Magdalena, P. et al. Bisphenol-A acts as a potent estrogen via non-
classical estrogen triggered pathways. Molecular and cellular endocrinology 355, 
201-207, doi:10.1016/j.mce.2011.12.012 (2012). 
35 Matthews, J. B., Twomey, K. & Zacharewski, T. R. In vitro and in vivo 
interactions of bisphenol A and its metabolite, bisphenol A glucuronide, with 
estrogen receptors alpha and beta. Chemical research in toxicology 14, 149-157 
(2001). 
36 Manna, P. R., Wang, X. J. & Stocco, D. M. Involvement of multiple transcription 
factors in the regulation of steroidogenic acute regulatory protein gene expression. 
Steroids 68, 1125-1134 (2003). 
37 Manna, P. R., Dyson, M. T. & Stocco, D. M. Regulation of the steroidogenic 
acute regulatory protein gene expression: present and future perspectives. 
Molecular human reproduction 15, 321-333, doi:10.1093/molehr/gap025 (2009). 
38 Ginsberg, M. D., Feliciello, A., Jones, J. K., Avvedimento, E. V. & Gottesman, 
M. E. PKA-dependent binding of mRNA to the mitochondrial AKAP121 protein. 
Journal of molecular biology 327, 885-897 (2003). 
39 Miller, W. L. & Auchus, R. J. The molecular biology, biochemistry, and 
physiology of human steroidogenesis and its disorders. Endocrine reviews 32, 81-
151, doi:10.1210/er.2010-0013 (2011). 
40 Stocco, D. M. et al. Elements involved in the regulation of the StAR gene. 
Molecular and cellular endocrinology 177, 55-59 (2001). 
41 Welshons, W. V., Nagel, S. C. & vom Saal, F. S. Large effects from small 
exposures. III. Endocrine mechanisms mediating effects of bisphenol A at levels 
of human exposure. Endocrinology 147, S56-69, doi:10.1210/en.2005-1159 
(2006). 
42 Giesbrecht, G. F. et al. Urinary bisphenol A is associated with dysregulation of 
HPA-axis function in pregnant women: Findings from the APrON cohort study. 
Environmental research 151, 689-697, doi:10.1016/j.envres.2016.09.007 (2016). 
 124 
43 Padmanabhan, V. et al. Maternal bisphenol-A levels at delivery: a looming 
problem? Journal of perinatology : official journal of the California Perinatal 
Association 28, 258-263, doi:10.1038/sj.jp.7211913 (2008). 
44 Feng, Y. et al. Effects of bisphenol analogues on steroidogenic gene expression 
and hormone synthesis in H295R cells. Chemosphere 147, 9-19, 
doi:10.1016/j.chemosphere.2015.12.081 (2016). 
45 Lan, H. C., Lin, I. W., Yang, Z. J. & Lin, J. H. Low-dose Bisphenol A Activates 
Cyp11a1 Gene Expression and Corticosterone Secretion in Adrenal Gland via the 
JNK Signaling Pathway. Toxicological sciences : an official journal of the Society 
of Toxicology 148, 26-34, doi:10.1093/toxsci/kfv162 (2015). 
46 Montanaro, D. et al. Antiestrogens upregulate estrogen receptor beta expression 
and inhibit adrenocortical H295R cell proliferation. Journal of molecular 
endocrinology 35, 245-256, doi:10.1677/jme.1.01806 (2005). 
47 Strauss, L. et al. Increased exposure to estrogens disturbs maturation, 
steroidogenesis, and cholesterol homeostasis via estrogen receptor alpha in adult 
mouse Leydig cells. Endocrinology 150, 2865-2872, doi:10.1210/en.2008-1311 
(2009). 
48 Couse, J. F., Yates, M. M., Walker, V. R. & Korach, K. S. Characterization of the 
hypothalamic-pituitary-gonadal axis in estrogen receptor (ER) Null mice reveals 
hypergonadism and endocrine sex reversal in females lacking ERalpha but not 
ERbeta. Molecular endocrinology (Baltimore, Md.) 17, 1039-1053, 
doi:10.1210/me.2002-0398 (2003). 
49 Stocco, D. M. & Selvaraj, V. Yet Another Scenario in the Regulation of the 
Steroidogenic Acute Regulatory (STAR) Protein Gene. Endocrinology 158, 235-
238 (2017). 
50 Caron, K. M. et al. Characterization of the promoter region of the mouse gene 
encoding the steroidogenic acute regulatory protein. Molecular endocrinology 
(Baltimore, Md.) 11, 138-147, doi:10.1210/mend.11.2.9880 (1997). 
51 Durando, M. et al. Neonatal expression of amh, sox9 and sf-1 mRNA in Caiman 
latirostris and effects of in ovo exposure to endocrine disrupting chemicals. 
General and comparative endocrinology 191, 31-38, 
doi:10.1016/j.ygcen.2013.05.013 (2013). 
52 Phrakonkham, P. et al. Dietary xenoestrogens differentially impair 3T3-L1 
preadipocyte differentiation and persistently affect leptin synthesis. The Journal 
of steroid biochemistry and molecular biology 110, 95-103, 
doi:10.1016/j.jsbmb.2008.02.006 (2008). 
53 Strakovsky, R. S. et al. Developmental bisphenol A (BPA) exposure leads to sex-
specific modification of hepatic gene expression and epigenome at birth that may 
 125 
exacerbate high-fat diet-induced hepatic steatosis. Toxicology and applied 
pharmacology 284, 101-112, doi:10.1016/j.taap.2015.02.021 (2015). 
54 Doshi, T., D'Souza, C., Dighe, V. & Vanage, G. Effect of neonatal exposure on 
male rats to bisphenol A on the expression of DNA methylation machinery in the 
postimplantation embryo. Journal of biochemical and molecular toxicology 26, 
337-343, doi:10.1002/jbt.21425 (2012). 
55 Christenson, L. K. et al. Oxysterol regulation of steroidogenic acute regulatory 
protein gene expression. Structural specificity and transcriptional and 
posttranscriptional actions. The Journal of biological chemistry 273, 30729-30735 
(1998). 
56 Walsh, L. P., McCormick, C., Martin, C. & Stocco, D. M. Roundup inhibits 
steroidogenesis by disrupting steroidogenic acute regulatory (StAR) protein 
expression. Environmental health perspectives 108, 769-776 (2000). 
57 Bosmann, H. B. et al. Acute in vivo inhibition of testosterone by endotoxin 
parallels loss of steroidogenic acute regulatory (StAR) protein in Leydig cells. 
Endocrinology 137, 4522-4525, doi:10.1210/endo.137.10.8828518 (1996). 
58 Fiedler, E. P., Plouffe, L., Jr., Hales, D. B., Hales, K. H. & Khan, I. Prostaglandin 
F(2alpha) induces a rapid decline in progesterone production and steroidogenic 
acute regulatory protein expression in isolated rat corpus luteum without altering 
messenger ribonucleic acid expression. Biology of reproduction 61, 643-650 
(1999). 
59 Dyson, M. T. et al. Mitochondrial A-kinase anchoring protein 121 binds type II 
protein kinase A and enhances steroidogenic acute regulatory protein-mediated 
steroidogenesis in MA-10 mouse leydig tumor cells. Biology of reproduction 78, 
267-277, doi:10.1095/biolreprod.107.064238 (2008). 
60 Stocco, D. M. & Clark, B. J. Regulation of the acute production of steroids in 
steroidogenic cells. Endocrine reviews 17, 221-244, doi:10.1210/edrv-17-3-221 
(1996). 
61 Bahat, A. et al. StAR enhances transcription of genes encoding the mitochondrial 
proteases involved in its own degradation. Molecular endocrinology (Baltimore, 
Md.) 28, 208-224, doi:10.1210/me.2013-1275 (2014). 
62 Granot, Z., Melamed-Book, N., Bahat, A. & Orly, J. Turnover of StAR protein: 
roles for the proteasome and mitochondrial proteases. Molecular and cellular 
endocrinology 265-266, 51-58, doi:10.1016/j.mce.2006.12.003 (2007). 
63 Stocco, D. M., Wang, X., Jo, Y. & Manna, P. R. Multiple signaling pathways 
regulating steroidogenesis and steroidogenic acute regulatory protein expression: 
more complicated than we thought. Molecular endocrinology (Baltimore, Md.) 
19, 2647-2659, doi:10.1210/me.2004-0532 (2005). 
 126 
64 Tajima, K. et al. The proteasome inhibitor MG132 promotes accumulation of the 
steroidogenic acute regulatory protein (StAR) and steroidogenesis. FEBS Lett 
490, 59-64 (2001). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 127 
4 BISPHENOL A STIMULATES ADRENAL CELL 
PROLIFERATION THROUGH ERb-MEDIATED 
ACTIVATION OF THE SONIC HEDGEHOG 
SIGNALING PATHWAY1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 The material in this chapter is based on a manuscript submitted to Journal of Steroid 
Biochemistry and Molecular Biology: Medwid S, Guan H, Yang K. Bisphenol A 
stimulates adrenal cortical cell proliferation via ERβ-mediated activation of the sonic 
hedgehog signaling pathway (2017).  
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4.1 Introduction 
In Chapter 2, I observed an increase in adrenal gland weight in adult mouse offspring 
prenatally exposed to BPA, with no changes in basal plasma ACTH levels. In this 
chapter, I sought to determine the cellular and molecular mechanisms that underlie BPA-
induced aberrant adrenal gland developmental phenotype using an in vitro cell model 
system. 
 
Bisphenol A (BPA) is one of the most well-known and prevalent endocrine disrupting 
chemicals, and has gained universal attention due to its adverse effects in humans and 
experimental animal models 1. BPA is widely used in the production of polycarbonate 
plastics and epoxy resins, such as food and beverage storage containers and thermal paper 
receipts 1,2. Biomonitoring studies have detected BPA in human saliva, milk, serum and 
urine collected globally 2. More alarming is the presence of BPA in human fetal blood, 
placental tissue and amniotic fluid 2,3. This has raised serious concerns about the impact 
of BPA exposure on the developing fetus during the critical period of organ maturation. 
Indeed, numerous studies have shown that BPA exerts adverse effects on many fetal 
organ systems, including the brain 4,5, lungs 6, liver 7, pancreas 8, heart 9, adrenal gland 
10,11, mammary gland 12,13, and ovary 14,15.  
We recently showed that prenatal exposure to BPA resulted in altered adrenal gland 
structure and function in adult mouse offspring 10. Specifically, absolute and relative 
adrenal gland weight was increased in both male and female adult offspring 10. Similarly, 
Panagiotidou et al. reported adrenal hyperplasia in juvenile female rat offspring following 
exposure to BPA during pregnancy and lactation 11. Alterations in adrenal weight and 
structure is normally associated with changes in plasma levels of adrenocorticotrophic 
hormone (ACTH). However, we did not observe an increase in basal plasma levels of 
ACTH, and concluded that BPA may directly affect adrenal gland weight independent of 
plasma ACTH in our prenatally BPA exposed mouse model 10. BPA has previously been 
shown to increase cell proliferation in various tissues, including breast cancer 16-18, 
ovarian cancer 19,20, neuroblastoma 21, Hela 22, prostate cancer 23, seminoma 24 and sertoli 
cells 25. However, the effects of BPA on adrenal cortical cell proliferation has never been 
examined.  
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Sonic hedgehog (shh) signaling pathway is a key mediator of embryonic development, as 
well as cell maintenance and tissue repair in adults 26,27. Specifically, the shh pathway is 
found to be activated during development, as well as in various forms of cancer due to its 
role in promoting cell proliferation through direct transcriptional activation of 
proliferation factors cyclin D1 and cyclin D2 26. Shh signaling components (shh, Gli, 
Patched 1) have been detected in human adrenal cortical cell lines, human fetal and adult 
adrenal glands, as well as both pediatric and adult adrenal tumors 28,29. Evidence of shh 
involvement in adrenal cell proliferation is demonstrated by the presence of an adrenal 
cortex hypotrophy phenotype in shh null mice 30,31. Thus, the present study was 
undertaken to determine (1) if BPA promotes adrenal cell proliferation, which may help 
explain the increased adrenal gland weight phenotype we reported in our previous study 
10; and (2) if so, whether the stimulatory effects of BPA on adrenal cortical cell 
proliferation are mediated through ERβ-mediated activation of the shh pathway using a 
human adrenal cortical cell line as an in vitro model system.  
4.2 Methods 
4.2.1 Reagents 
Bisphenol A was purchased from Sigma-Aldrich Canada Ltd. (CAS 80-05- 7; Oakville, 
ON) and dissolved in ethanol to prepare 10 mM stock solution, and stored at -20°C. 
Cyclopamine was purchased from Toronto Research Chemicals (C988400; Toronto, 
ON), dissolved in ethanol to prepare 10 mM stock solution and stored at -20°C. 2,3-bis(4-
Hydroxyphenyl)-propionitrile (DPN) and 4-[2-Phenyl-5,7-
bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol (PHTPP) were purchased from 
Tocris Bioscience (cat. no. 1494; Minneapolis, MN) and Abcam (ab145148; Toronto, 
ON), respectively, dissolved in ethanol to a concentration of 100 mM, and stored at -
20°C.  
4.2.2 Cell Culture 
The adrenocortical human cell line NCI-H295 cell line was derived from an adrenal 
tumor of a 48-year-old female and was first described by Gazdar et al. 32. The NCI-H295 
cell line expresses all steroidogenic enzymes present in the human fetal adrenal glands 
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and is an established model to study adrenal steroidogenesis 33. The subline, NCI-H295A, 
was further derived and characterized from the H295R cell line, and is currently the best 
available model of human fetal adrenal gland cells 34. H295A cells (generously provided 
by Dr. Walter L. Miller) were cultured in RPMI 1640 media (Invitrogen) with 2% fetal 
bovine serum (FBS; Sigma), 0.1% insulin-transferrin-selenium supplement (Sigma 
I18884) and 100IU penicillin and 100µg/mL were starved in serum-free media 24 h 
before treatment, and cultured in 0.2% FBS media throughout treatments.  
4.2.3 Western Blot Analysis 
 Levels of various proteins were analyzed using standard western blot analysis, as 
previously described 35. Briefly, cells were lysed in SDS gel loading buffer (50mM Tris-
HCL, pH 6.8, 2% wt/vol SDS, 10% vol/vol glycerol, 100mM DTT and 0.1% wt/vol 
bromophenol blue) to be loaded to a standard SDS-PAGE gel. Protein was then 
transferred to a PVDF transfer membrane (Amersham Hybond-P, cat. no. RPN303F, GE 
Healthcare Lifesciences, Baie D'Urfe, QC), and blocked overnight with 5% milk in TTBS 
(0.1% vol/vol Tween-20 in TBS). Membranes were then probed with primary antibodies 
for 1-2 hours at room temperature (Table 4.1). Washing was done with TTBS, 3×10 
minutes before labeling with horseradish peroxidase-labeled secondary antibody (Table 
4.1), for 1 hour at room temperature. After 3×10 minute TTBS washes, protein were 
detected using ECL and visualized using chemiluminescence (cat. no. WBLUR0500, 
Luminata Crescendo, Western HRP Substrate; Millipore, Etobicoke, ON) and captured 
on the VersaDoc Imaging System (BioRad). Densitometry was performed using Image 
Lab Software, comparing levels of proteins expressed as percent of controls.  
 
 
 
 
 131 
Table 4.1: Primary and secondary antibodies used for western blotting. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Antibody Company Catalog Number Dilution Used 
PCNA Cell Signalling 2586 1:5000 
GAPDH Imgenex IMG-5567 1:10000 
Cyclin D1 Santa Cruz Sc-717 1:500 
Cyclin D2 Cell Signalling 3741 1:1000 
ERβ Santa Cruz Sc-8974 1:1000 
Gli1 Abcam ab49314 1:500 
Shh Santa Cruz Sc-365112 1:200 
β-tubulin Imgenex IMG-5810A 1:1000 
Lamin B1 Abcam Ab16048 1:20000 
Anti-Rabbit R&D systems HAF008 1:3000 
Anti-mouse BIO RAD 170-6516 1:7500 
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4.2.4  Cell Number Assessment 
Cells were seeded in 2% FBS-RMPI 1640 culture medium and were incubated overnight. 
After 24 h serum starvation, the medium was changed to 0.2% FBS RMPI 1640 
containing 10 nM BPA. After 72 h incubation, the cells trypsinized, added in equal 
volumes to trypan blue stain 0.4% (Invitrogen T10282) and counted with Countess 
Automated cell counter (Invitrogen C10277).  
4.2.5 Real-time quantitative RT-PCR 
The relative abundance of various mRNAs was determined by a two-step real time 
quantitative RT-PCR (qRT-PCR), as described previously 36, with the following 
modifications. Briefly, total RNA was extracted from cells using RNeasy Mini Kit 
(Qiagen Inc., Mississauga, ON) coupled with on-column DNase digestion with the 
RNase-free DNase Set (Qiagen) according to the manufacturer’s instructions. One 
microgram of total RNA was reverse-transcribed in a total volume of 20 µl using the 
High Capacity cDNA Archive Kit (Applied Biosystems, Forest City, CA) following the 
manufacturer’s instructions. For every RT reaction set, one RNA sample was set up 
without reverse-transcriptase enzyme to provide a negative control. Gene transcript levels 
of GAPDH, GLI1 and SHH were quantified separately by pre-designed and validated 
TaqMan® Gene Expression Assays (Applied Biosystems; Table 4.2) following the 
manufacturer’s instructions. Briefly, gene expression assays were performed with the 
TaqMan® Gene Expression Master Mix (Applied Biosystems P/N #4369016) and the 
universal thermal cycling condition (2 min at 50 °C and 10 min at 95 °C, followed by 40 
cycles of 15 s at 95 °C and 1 min at 60 °C) on the ViiATM 7 Real-Time PCR System 
(Applied Biosystems).  
The relative amounts of various gene-specific mRNAs in each RNA sample was 
quantified by the comparative CT method (also known as ΔΔ CT method) using the 
Applied Biosystems relative quantitation and analysis software according to the 
manufacturer’s instructions. For each experiment, gene specific mRNAs were normalized 
to the housekeeping gene GAPDH. The amount of various gene-specific mRNAs under 
different treatment conditions is expressed relative to the amount of transcript present in 
the untreated control. 
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Table 4.2: TaqMan® gene expression assays for the human genes analyzed. 
 
Gene Name Assay ID 
SHH Hs00179843_m1 
GLI1 Hs00171790_m1 
GAPDH Hs02758991_g1 
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4.2.6 Statistical Analysis  
Results are presented as group means ± SEM of four independent experiments, as 
indicated. Data was analyzed using a Student’s t-test or a one-way ANOVA, followed by 
a Tukey’s post hoc; statistical significance was set at P<0.05. Statistical analysis was 
performed using statistical software GraphPad Prism Version 5 Software.  
4.3 Results 
4.3.1 Time- and concentration-dependent effects of BPA on cell 
proliferation.  
As a first step in determining the effects of BPA on cell proliferation, protein levels of 
PCNA, a universal marker of cell proliferation, were assessed over time. Levels of PCNA 
protein were unchanged at 24 and 48 h, but were significantly elevated at 72 h following 
treatment with 10 nM of BPA (Figure 4.1A). A similar trend of change was observed in 
cell number following BPA treatment (Figure 4.1B). We then treated cells with 
increasing concentrations of BPA (1-1000 nM) for 72 h, and showed that this treatment 
resulted in a concentration-dependent increase in PCNA protein levels such that the 
maximal effect was observed at 10 nM BPA (Figure 4.1C).  
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Figure 4.1: Time- and concentration-dependent effects of BPA on cell proliferation. 
H295A cells were treated with 10 nM of BPA for various times (24-72 h) or increasing 
concentrations (1-1000 nM) of BPA for 72 h. At the end of treatment, levels of PCNA (a 
universal marker of proliferation) (A, C) and cell number (B) were determined by 
western blotting and cell counting, respectively. Data are presented as mean ± SEM 
(*P<0.05, ***P<0.001 vs. control; n=4 independent experiments).  
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4.3.2 Effects of BPA on the expression of key cell proliferation 
factors.  
To further examine the effects of BPA on cell proliferation, protein levels of the two key 
proliferation factors, cyclin D1 and cyclin D2, were determined. Although levels of both 
cyclin D1 and cyclin D2 proteins were unchanged after 48 h of BPA treatment (Figure 
4.2A), they were significantly increased after 72 h of BPA treatment (Figure 4.2B).  
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Figure 4.2: Effects of BPA on key cell proliferation factors. 
H295A cells were treated with 10 nM of BPA for 48 h (A) or 72 h (B). At the end of 
treatment, levels of the two key cell proliferation factors, cyclin D1 and cyclin D2 were 
determined by western blotting. Data are presented as mean ± SEM (**P<0.01 vs. 
control; n=4 independent experiments).  
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4.3.3 Effects of BPA on selected components of the shh signaling 
pathway.  
Shh signaling is known to be essential for adrenal development and proliferation. Adrenal 
specific shh knockout mice display severe adrenal hypoplasia, specifically an 
underdeveloped cortex in fetal and adult mice 30,37. To explore the role of shh signaling in 
mediating BPA-induced cell proliferation, changes in key shh signaling pathway 
components were examined. Levels of shh mRNA, but not Gli1 mRNA, were increased 
at 48 h post BPA treatment (Figure 4.3A&B). In contrast, protein levels of both shh and 
Gli1 were elevated following 48 h of BPA treatment (Figure 4.3C&D), which returned 
to control levels at 72 h (Figure 4.3E&F). 
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Figure 4.3: Effects of BPA on selected components of the shh signaling pathway. 
H295A cells were treated with 10 nM of BPA for 48 h. At the end of treatment, levels of 
shh mRNA (A) and Gli1 mRNA (B) were determined by qRT-PCR. Levels of shh 
protein (C&E) and Gli1 protein (D&F) at 48 h (C&D) and 72 h (E&F) were determined 
by western blotting. Data are presented as mean ± SEM (*P<0.05, **P<0.01, vs. control; 
n=4 independent experiments).  
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4.3.4 Effects of BPA on activity of the shh signaling pathway.  
Activation of the shh signaling pathway involves translocation of the shh transcription 
factor Gli1 from cytoplasm to the nucleus where it acts as an activator of shh target genes 
38,39. To determine if BPA activates the shh signaling pathway, we measured Gli1 protein 
levels in cytosolic and nuclear fractions following treatment with BPA for 48 h. BPA 
treatment significantly increased Gli1 protein in nuclear but not cytosolic fraction 
(Figure 4.4A&B). To ascertain if BPA activation of the shh signaling pathway is ligand-
dependent, we used cyclopamine (Cyc), which blocks the shh pathway at the SMO 
receptor. We treated cells with BPA in the presence and absence of Cyc, and examined 
changes in Gli1 protein. We found that Cyc prevented BPA-induced increases in Gli1 
protein levels (Figure 4.4C).  
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Figure 4.4: Effects of BPA on activity of the shh signaling pathway  
H295A cells were treated with 10 nM BPA for 48 h. At the end of the treatment, levels of 
Gli1 protein in cytosolic (A) and nuclear (B) extracts were determined by western 
blotting. Alternatively, H295A cells were treated with either 10 nM BPA, 10 µM 
cyclopamine (Cyc) or both for 48 h. At the end of treatment, levels of Gli1 protein were 
determined by western blotting (C). Data are presented as mean ± SEM (*P<0.05 vs. 
control; different letters indicate statistically significant differences among groups; n=4 
independent experiments). 
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4.3.5 Effects of shh pathway inhibition on BPA-induced cell 
proliferation markers.  
Shh signaling is known to induce cell proliferation in a variety of tissues 26,40,41. 
Specifically, the transcription factor Gli1 is known to directly stimulate the transcription 
of cyclin D1 and D2 genes, CCND1 and CCND2 26. To provide functional evidence for 
the involvement of the shh signaling pathway in mediating BPA-induced cell 
proliferation, we assessed changes in protein levels of PCNA, cyclin D1 and D2 
following treatment with BPA in the presence and absence of the shh pathway inhibitor 
Cyc. Cyc completely blocked BPA-induced increases in protein levels of PCNA (Figure 
4.5A), as well as cyclin D1 and D2 (Figure 4.5B).  
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Figure 4.5: Effects of shh inhibition on BPA-induced cell proliferation markers. 
H295A cells were treated with 10 nM BPA, 10 µM cyclopamine (Cyc) or both for 72 h. 
At the end of treatment, levels of PCNA (A), cyclin D1 and cyclin D2 (B) were 
determined by western blotting. Data are presented as mean ± SEM (Different letters 
indicate statistically significant differences among groups; n=4 independent 
experiments).  
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4.3.6 Effects of BPA on estrogen receptor β expression and 
activity 
The translocation of ER from cytosol to the nucleus is essential for transcriptional 
activation of estrogen target genes 42-44. To examine if BPA activates ERβ, we measured 
protein levels of ERβ in total cell lysates as well as cytosolic and nuclear fractions 
following BPA treatment for 48 h. Although BPA treatment did not alter total ERβ 
protein levels (Figure 4.6A), it decreased cytosolic while increasing nuclear levels of 
ERβ protein (Figure 4.6B&C).  
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Figure 4.6: Effects of BPA on estrogen receptor β expression and activity. 
H295A cells were treated with 10 nM of BPA for 48 h. At the end of treatment, levels of 
ERβ protein in total (A) cytosolic (B) and nuclear (C) extracts were subjected to western 
blotting. Data are presented as mean ± SEM (**P<.0.01 vs. control; n= 4 independent 
experiments).  
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4.3.7 Effects of DPN and PHTPP on BPA-induced cell proliferation 
markers.  
We then investigated the involvement of ERβ in BPA-induced cell proliferation using the 
ERβ specific agonist DPN and the ERβ specific antagonist PHTPP. Treatment with DPN 
significantly increased protein levels of PCNA (Figure 4.7A) as well as cyclin D1 and 
cyclin D2 (Figure 4.7C) at 72 h. Furthermore, pretreatment with PHTPP completely 
prevented BPA-induced increases in levels of PCNA (Figure 4.7B), cyclin D1 and cyclin 
D2 (Figure 4.7D) proteins.  
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Figure 4.7: Effects of DPN and PHTPP on BPA-induced cell proliferation markers. 
H295A cells were treated with 10 nM DPN, 10 nM BPA, 100 nM PHTPP, or both 
PHTPP and BPA for 72 h. At the end of treatment, levels of PCNA protein (A&B), 
cyclin D1 and cyclin D2 protein (C&D) were determined by western blotting. Data are 
presented as mean ± SEM (**P<0.01, ***P<0.001 vs. control; different letters indicate 
statistically significant differences among groups; n=4 independent experiments). 
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4.3.8 Effects of DPN and PHTPP on BPA-induced activation of the 
shh signaling pathway.  
ERa has been shown to increase shh activity in breast 45,46 and gastric 47 cancer cells. 
However, this effect has yet to be shown with ERβ. Therefore, we tested the hypothesis 
that BPA acts through ERβ to activate the shh signaling pathway. We showed that the 
ERβ specific agonist DPN increased protein levels of both shh and Gli1 after 48 h 
treatment (Figure 4.8A&C). Importantly, the ERβ specific antagonist PHTPP completely 
blocked BPA-induced increases in both shh and Gli1 protein levels (Figure 4.8B&D).  
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Figure 4.8 Effects of DPN and PHTPP on BPA-induced shh pathway activation. 
H295A cells were treated with 10 nM DPN, 10 nM BPA, 100 nM PHTPP, or both 
PHTPP and BPA for 48 h. At the end of treatment, levels of shh protein (A&B) and Gli1 
protein (C&D) were determined by western blotting. Data are presented as mean ± SEM 
(**P<0.01 vs. control; different letters indicate statistically significant differences among 
groups; n=4 independent experiments). 
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4.4 Discussions 
Proper adrenal gland development is essential for adrenal steroidogenesis, particularly 
glucocorticoid production in later-life. We recently demonstrated that prenatal exposure 
to BPA resulted in abnormal adrenal gland development and function in adult mouse 
offspring, including increased adrenal gland weight independent of plasma ACTH levels 
10. However, the molecular mechanisms underlying the BPA-induced increase in adrenal 
gland weight remain unknown. Therefore, the present study was designed to address this 
important question using the best available model of fetal adrenal cortical cells, the 
H295A cell line. We have demonstrated that BPA stimulates adrenal cell proliferation via 
ERβ-mediated activation of the shh signaling pathway. Thus, our present findings reveal 
a plausible molecular mechanism by which BPA influences adrenal gland development 
and function.  
The concentration of BPA used in this study (10 nM) is in line with those used in 
previous in vitro studies 48. Importantly, this concentration (equivalent to 2.28 ng/ml) is 
well within the range previously reported in plasma (0.5-22.3 ng/ml) 49  and urine (0.16-
43.42 ng/ml) 50 of pregnant women in North American.  
BPA has been shown to influence cell proliferation in both in vivo and in vitro models. In 
experimental animal models, prenatal exposure to BPA led to increased cell proliferation 
in fetal liver 7, prostate 51, pancreas 52, and pituitary gland 53. In contrast, offspring of rats 
exposed to BPA during pregnancy and lactation showed decreased proliferation in neural 
stem cells of the hypothalamus and sub-ventricular zone 54. In several in vitro models, 
BPA increases cell proliferation at various concentrations 16-25. Interestingly, in sertoli 
cells, nanomolar concentrations of BPA induced cell proliferation, while micromolar 
concentrations decreased cell proliferation, suggesting that the effect of BPA on cell 
proliferation is concentration-dependent 55. To the best of our knowledge, we are the first 
to demonstrate that BPA, at environmentally relevant concentrations, significantly 
increases cell number as well as the expression of PCNA, cyclin D1 and D2, three key 
markers of cell proliferation, in adrenal cortical cells. This indicates that BPA stimulates 
adrenal cortical cell proliferation. Thus, our present study provides a plausible cellular 
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mechanism by which prenatal BPA exposure results in increased adrenal gland weight in 
adult mouse offspring 10. 
Activation of the shh signaling pathway is known to increase the transcription of genes 
encoding both cyclin D1 and D2 genes, leading to increased cell proliferation 26.  
Recently, BPA has been shown to increase levels of microRNA-107 (miRNA-107), 
which inhibits the expression of suppressor of fused homolog (SUFU) and GLI family 
zinc finger 3 (Gli3) in human endometrial cancer in RL95-2 cells 56. Both SUFU and Gli3 
are repressors of the shh signaling pathway, thus BPA-induced suppression of these 
proteins may potentially lead to the activation of shh signaling and consequently 
increased proliferation in endometrial cells 56. Therefore, we investigated the possibility 
that the BPA-induced adrenal cortical cell proliferation may be mediated via activation of 
the shh signaling pathway. As a first step in examining this possibility, we determined the 
effects of BPA on shh expression, and found that levels of both shh mRNA and protein 
were increased after 48 hours of BPA treatment, which preceded the increase in cell 
proliferation we observed at 72 hours.  
An increase in shh protein and secretion results in its binding to the transmembrane 
receptor Patched 1 (Ptch1), which prevents Ptch1 from inhibiting another transmembrane 
protein smoothened (SMO) 38,39. SMO can then be released from the plasma membrane 
into the cytoplasm, leading to the release of a complex containing the transcription 
factors Gli1-3, allowing them to translocate to the nucleus to regulate transcription of 
target genes 38,39. Specifically, the nuclear translocation of the positive transcriptional 
regulator Gli1, is considered a marker of shh signaling activation 38,39. Therefore, we 
investigated the potential for BPA to alter Gli1 protein and mRNA levels. We found that 
although BPA did not alter Gli1 mRNA, it increased Gli1 protein levels at 48 hours. The 
regulation of Gli1 at post-transcriptional level is well established and could be a result of 
changes in translation and phosphorylation efficiency 57,58. Furthermore, BPA 
significantly increased Gli1 protein levels in the nuclear fraction without altering those in 
the cytosolic fraction, suggesting that BPA enhanced nuclear translocation of Gli1, and 
consequently the activity of the shh signaling pathway. Given the observed increase in 
Gli1 protein levels in total cell lysates, the relatively minor and non-significant decrease 
seen in cytosolic Gli1 levels is consistent with our notion of an enhanced Gli1 nuclear 
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translocation following BPA treatment. It is known that activation of the shh signaling 
pathway is mediated through either the ligand-dependent or the ligand-independent 
pathway 59. To determine if BPA acts through the ligand-dependent shh signaling 
pathway, we examined the effects of BPA on Gli1 protein levels in the presence and 
absence of cyclopamine. Cyclopamine is a potent inhibitor of the shh signaling pathway 
by preventing release and translocation of the SMO receptor. In the present study, we 
showed that cyclopamine blocked the effects of BPA on Gli1 protein levels, indicating 
that BPA activates the shh pathway through the ligand-dependent pathway.  
To ascertain whether BPA-induced activation of the shh signaling pathway leads to 
increased cell proliferation, we treated cells with BPA in the presence and absence of 
cyclopamine. We found that cyclopamine completely abrogated the stimulatory effects of 
BPA on cell proliferation, as indicated in protein levels of PCNA, cyclin D1 and D2. 
Taken together, these results demonstrate the involvement of the shh signaling pathway 
in BPA-induced adrenal cortical cell proliferation.  
It is well known that BPA acts as an ERβ agonist, with a higher affinity for ERβ than 
ERa 60,61. Furthermore, ERβ is the dominant estrogen receptor expressed in human 
H295R adrenal cortical cells 62. Therefore, we then investigated the role of ERβ in BPA-
induced cell proliferation and shh activation. Given that a key step in ERβ activation is its 
rapid nuclear translocation upon binding to its ligand 63, we determined the effects of 
BPA on ERβ translocation at 48 h. This time point was chosen based on the BPA-
induced increase in shh mRNA at 48 h. We found that levels of ERβ protein were 
increased in the nuclear fraction but decreased in the cytosolic fraction following BPA 
treatment, indicating that BPA enhanced translocation of ERβ to the nucleus in H295A 
cells. However, it is likely that the BPA-induced increase in ERβ nuclear translocation 
may have occurred earlier than 48 h. 
Although estrogen has previously been shown to increase adrenal cell proliferation in 
both animal models 64  and the H295R cell line 62. We then sought to determine if 
activation of ERβ stimulates adrenal cell proliferation using the ERβ selective agonist 
DPN. We showed that DPN increased protein levels of the three key proliferation 
markers, PCNA, cyclin D1 and D2, indicating that the activation of ERβ by DPN led to 
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increased cell proliferation. To provide evidence for the involvement of ERβ in mediating 
BPA-induced cell proliferation, we treated cells with BPA in the presence and absence of 
the ERβ-specific antagonist PHTPP. We found that PHTPP completely blocked the 
stimulatory effects of BPA on PCNA, cyclin D1 and D2 protein. Taken together, these 
results demonstrate that ERβ mediates BPA-induced proliferation in adrenal cells.  
The ability of estradiol to activate the shh signaling pathway has previously been 
demonstrated in ERa positive breast and gastric cancer cells 45-47, however it remains 
unknown if a similar effect can be observed through ERβ. Therefore, to determine if ERβ 
activates the shh signaling pathway in adrenal cells, we examined the effects of ERβ 
specific agonist DPN on expression of the two key proteins in the shh signaling pathway. 
We found that DPN increased both shh and Gli1 protein levels, indicating a novel link 
between ERβ and shh activation. We then determined if the activation of ERβ by BPA 
leads to activation of the shh signaling pathway. We treated cells with BPA in the 
presence and absence of ERβ-specific antagonist PHTPP, and found that PHTPP 
abrogated the stimulatory effects of BPA on shh and Gli1 protein levels. Collectively, 
these results indicate that BPA stimulates adrenal cell proliferation via ERβ-induced 
activation of the shh signaling pathway.  
In conclusion, the present study demonstrates for the first time that BPA acts on ERβ to 
activate the shh signaling pathway, which in turn leads to increased proliferation in 
H295A cells. Thus, our present study reveals a novel BPA-induced cell proliferation 
signalling pathway that may underlie the increased adrenal gland weight phenotype we 
reported previously in prenatally BPA exposed adult mouse offspring.  
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5.1 Summary  
This thesis utilizes both in vivo and in vitro approaches aimed at determining the effects 
of prenatal exposure to environmentally relevant doses of BPA on adrenal gland 
development and steroidogenic function. Prenatal exposure to BPA resulted in altered 
adrenal steroidogenesis, as evidenced by increased plasma corticosterone levels. 
However, there were no corresponding changes in plasma levels of ACTH. The increased 
plasma corticosterone in female offspring was likely a result of enhanced adrenal 
expression of StAR, the rate limiting factor of steroidogenesis. However, adrenal StAR 
expression was not altered in male offspring, suggesting that BPA exerted sex-specific 
effects on adrenal StAR expression. Using the H295A cell line as an in vitro model 
system, I demonstrated that BPA induced StAR protein expression through an ERa- 
and/or ERb-mediated unknown mechanism that was independent of transcription, 
translation, and protein half-life. I also provided evidence that BPA increased adrenal 
cortical cell proliferation in vitro via a novel molecular mechanism that involves ERb-
mediated activation of the Shh signaling pathway. Taken together, these findings 
demonstrate that prenatal BPA exposure at environmentally relevant doses disrupts 
adrenal gland development and steroidogenic function specifically pertaining to 
glucocorticoid production. They also suggest that BPA-induced aberrant adrenal gland 
development and steroidogenic function help explain alterations in plasma glucocorticoid 
levels and HPA dysfunction seen in epidemiological 1,2 and experimental animal studies 
3-6. 
5.1.1 Doses and concentrations of BPA used in in vivo and in vitro 
experiments  
The dose of BPA used in Chapter 2 (25 mg BPA/kg diet; equivalent to 5 mg BPA/kg 
body weight) was chosen based on our previous prenatal exposure dose-response studies 
in which impaired fetal lung, pancreas, and liver maturation were induced without any 
effect on fetal body weight or litter size 7-9. This dose is also one tenth of the LOAEL 
reported for rodents (50 mg/kg/day), as determined by the U.S. Environmental Protection 
Agency (IRIS 2012). Importantly, maternal plasma concentrations of BPA in our mouse 
model were determined to be 1.7 ng/ml, measured using GC–MS 7. The concentration of 
BPA (10 nM) used throughout Chapters 3 and 4 is equivalent to 2.28 ng/ml, which is 
 162 
consistent with previous in vitro studies 10. The doses and concentrations of BPA used in 
both in vivo and in vitro experiments are at the lower end of the exposure range reported 
in the plasma (0.5-22.3 ng/ml) 11  and urine (0.16-43.42ng/ml) 1,2 of pregnant women in 
the North America. Additionally, pharmacokinetic studies have shown that oral 
administration of unconjugated BPA resulted in similar plasma levels in rodents and non-
human primates 12. Thus, the dosages of BPA as well as the mouse model and the adrenal 
cortical cell line used in this thesis are relevant to human exposure.  
5.1.2 Prenatal BPA disrupts adrenal steroidogenesis in a sex-
specific manner 
Exposure to EDC during critical periods of organ maturation affect lifelong organ 
structure and function, leading to disease and dysfunction later in life 13,14. Evidence 
suggests that EDC exposure during fetal development can lead to HPA axis programming 
alterations, resulting in HPA and adrenal dysfunction in adulthood 15,16. As such, prenatal 
BPA exposure in humans is associated with HPA axis dysfunction in both pregnant 
women and 3-month old infants 1,2. In addition, animal studies have shown that perinatal 
BPA exposure caused HPA dysfunction in adult offspring, resulting in changed gene 
expression in the hypothalamus and pituitary, and altered plasma levels of CRH, ACTH, 
and glucocorticoid 3-6. Moreover, Panagiotidou, et al. 6 demonstrated that BPA exposure 
during pregnancy and lactation resulted in increased adrenal gland weight and abnormal 
adrenal cortex zone thickness. Taken together, these findings suggest that developmental 
exposure to BPA can disrupt the HPA axis and adrenal gland development, leading to 
altered adrenal function in adulthood.  
In Chapter 2, the effects of developmental BPA exposure on adrenal function were 
assessed by examining the hypothesis that prenatal exposure to environmentally relevant 
doses of BPA disrupts adrenal gland development and steroidogenic function in adult 
mouse offspring. This study demonstrated that prenatal BPA exposure led to increased 
basal plasma corticosterone levels independent of ACTH levels in both male and female 
adult offspring. However, protein levels of StAR and cyp11A1, the two rate limiting 
factors of steroidogenesis, were only increased in female offspring adrenal glands, 
demonstrating the sex-specific effects of BPA.  
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These findings are supported by numerous studies demonstrating the adverse effects of 
other environmental chemicals on adrenal steroidogenesis. As described in Table 5.1, 
pesticides, fungicides and insecticides (atrazine, imazalil, prochloraz, lindane, and 3-
methylsulfonyl-2,2-bis(4-chlorophenyl)-1,1-dichloroethene (3-MeSO2-DDE)) 17-23, 
phytoestrogens (diadzein and geinstein) 18,21,22, organophosphates (Diethylumbelliferyl 
phosphate and dimethoate) 18,24,25, nicotine 26, cadmium 18, mercury 27, and nonlyphenol 28 
have all been shown to alter adrenal steroidogenesis by disturbing steroidogenic enzymes 
and the downstream production of steroid hormone levels.  
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Table 5.1: Environmental chemicals that alter adrenal steroidogenesis. 
Environmental chemical Structural/ functional impact Reference 
Atrazine Cyp19 inducer 17 
Imazalil 
Inhibit steroidogenic enzymes 
 
Decreased cortisol and aldosterone 
secretion 
19 
 
21,22 
 
 
Prochloraz 
Inhibit cortisol and aldosterone 
secretion through inhibition of cyp17 
18 
Lindane 
Increased steroidogenic enzymes and 
StAR promotor activity 
20 
3-MeSO2-DDE 
Inhibit cortisol secretion through 
interaction with cyp11B1 
18,23 
Diadzein 
Inhibit activity but not expression of 
3b-HSD 
Decreased cortisol and aldosterone 
secretion 
21,22 
 
18 
Geinstein 
Inhibit activity but not expression of 
3b-HSD 
21,22 
 
Diethylumbelliferyl phosphate 
Decreased cortisol and aldosterone 
secretion 
18 
Dimethoate 
Decreased cortisol and aldosterone 
secretion 
Inhibited StAR transcription 
18 
 
25 
Nicotine Inhibit transcription of StAR 26 
Cadmium 
Decreased cortisol and aldosterone 
secretion 
18 
Mercury 
Inhibit testosterone and progesterone 
levels 
27 
4-nonylphenol 
Decreased progesterone and increased 
testosterone and 17b-estradiol levels 
28 
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Importantly, evidence suggests that dysfunction of the HPA axis during fetal 
development results in increased glucocorticoid levels in adults, leading to an increased 
risk for depression and other mood disorders 29,30. Thus, these studies provide a possible 
mechanism behind BPA’s association with neurological and behavioural disorders such 
as depression and anxiety 5,31.  
 
Feedback and signaling pathways are essential for maintaining proper adrenal gland 
development and function, and thus any alterations in these pathways may lead to disease 
and dysfunction 32-35.  Furthermore, there are a variety of transcription factors and 
receptors that are essential for proper developmental processes and can be altered during 
the critical period of organogenesis 32,33. Previous experimental animal studies have 
provided evidence for an important role of the following factors and signaling pathways 
in adrenal development: (1) steroid hormone receptors such as ER 36 and glucocorticoid 
receptors 33; (2) Shh 37 and IGF signaling 38; and (3) transcription factors, such as SF-1 39 
and DAX-1 40. Alterations in any of these factors result in abnormal adrenal development 
and can potentially lead to altered adrenal function in adult life. Therefore, it is likely that 
prenatal BPA disrupts fetal adrenal development by altering one or more of these factors 
and signaling pathways.  
5.1.3 BPA stimulates StAR protein expression through estrogen 
receptor signaling 
In Chapter 2, I demonstrated that prenatal BPA exposure increased expression of the rate-
limiting factor of adrenal steroidogenesis, StAR, in adult female mouse offspring 41. 
Therefore, H295A cells, the best available model of human fetal adrenal cortical cells, 
were used an in vitro model system to investigate the underlying molecular mechanisms.  
As shown in Chapter 3, BPA treatment increased StAR protein levels in a concentration-
dependent manner, indicating that these cells were a suitable in vitro model system. 
Chronic induction of the rate-limiting step of adrenal steroidogenesis, StAR, suggests a 
permanent upregulation of the steroidogenic pathway. This would result in an increase in 
the production of glucocorticoids, which may lead to long term diseases such as 
depression, anxiety, metabolic dysfunction, and glucocorticoid resistance. Additionally, 
this sustained increase in adrenal steroidogenesis would suggest that BPA may disrupt 
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HPA axis function. This is consistent with previous literature suggesting BPA affects the 
HPA axis at the level of the hypothalamus and pituitary gland 3,5.  
Since the ER pathway has been shown to be critical for adrenal gland development, 
specifically for cortical development and ACTH receptor sensitivity 42, the possible 
involvement of ER signaling was examined with BPA treatment. The ERa and ERb 
isoform specific agonists PPT and DPN, respectively, were used to determine if ERa 
and/or ERb were involved in regulating StAR expression. I demonstrated that both PPT 
and DPN mimicked while the ER antagonist ICI blocked the stimulatory effects of BPA 
on StAR protein levels. These findings suggested that the BPA-induced StAR protein 
expression is likely mediated by ERa and/or ERb. They also revealed a novel role of 
these two nuclear ERs in regulating adrenal StAR expression, and consequently adrenal 
steroidogenesis.   
I then elucidated the precise molecular mechanism by which BPA, via ERs, induces 
StAR protein expression. First, I examined if BPA could be interfering with the 
transcription of StAR mRNA, and found that levels of StAR mRNA were unchanged 
after BPA treatment. This suggested that BPA did not affect StAR gene transcription. 
Previous studies have found that StAR protein levels can be altered independent of 
changes in StAR mRNA after exposure to oxysterols 43, pesticides 44, endotoxins 45 and 
prostaglandins 46. However, the post-transcriptional mechanisms behind these effects 
were not examined.  
Next, I examined if BPA altered the translation of the 37-kDa StAR pre-protein, which 
was found to be unchanged after BPA exposure, suggesting that BPA did not alter StAR 
translation. The StAR pre-protein is cleaved into the mature 30-kDa isoform at the OMM 
and transported to the IMM following cholesterol transport 47,48. If BPA interfered in the 
processes of StAR cleavage or transport, there would not only be a change in the mature 
StAR protein levels but also a reciprocal change in the 37-kDa pre-protein. Therefore, 
since there was no change in StAR pre-protein levels, it is unlikely that BPA affected 
StAR cleavage or transport.   
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Lastly, I determined if BPA affected the half-life of StAR protein, and found that it was 
unchanged following BPA treatment. An increase in mature StAR protein build-up in the 
mitochondria is normally associated with an increase in corresponding proteases (LON 
and AFG3L2) responsible for StAR degradation to prevent a novel form of mitochondrial 
stress, termed StAR overload response (SOR) 49,50. Thus, the BPA-induced increase in 
StAR protein levels independent of alterations in the half-life of StAR protein suggests 
that BPA may alter the SOR. This buildup of StAR protein in the mitochondria may lead 
to alterations in mitochondria structure and function 49.   
Collectively, these findings suggest that BPA increases StAR protein levels likely 
through ERa and/or ERb  in adrenal cortical cells that involve an unknown novel 
mechanism independent of StAR gene transcription, translation, and protein half-life. 
Nevertheless, BPA-induced increases in StAR protein suggest the induction of adrenal 
steroidogenesis, and consequently an increase in glucocorticoid production. However, 
future research is required to decipher the precise molecular mechanisms behind these 
effects to help better understand the adverse effects of BPA, as well as other EDCs, on 
adrenal gland steroidogenesis.  
5.1.4 BPA stimulates adrenal cortical cell proliferation through 
ERb-mediated activation of the Shh pathway 
In Chapter 2, I demonstrated that prenatal BPA exposure increased both absolute and 
relative adrenal gland weight without a change in plasma ACTH levels in adult mouse 
offspring 41. Increased adrenal weight is normally a result of high plasma ACTH levels 51. 
However, I did not observe an increase in basal plasma levels of ACTH, and concluded 
that BPA likely affects adrenal gland weight independent of ACTH in our prenatal BPA 
exposed mouse model 41. Therefore, I addressed this possibility in Chapter 4 using the 
H295A cell line as an in vitro model system. Proliferation in the adrenal gland is essential 
for development and remodeling in the adult 35,52. I demonstrated that BPA treatment of 
H295A cells induced proliferation, as evidenced by increased levels of PCNA (a 
universal proliferation marker), and key proliferation factors cyclins D1 and D2.  
The Shh signaling pathway is heavily involved in the development and formation of the 
adrenal glands, and Shh knockout mice display a severe hypotrophic adrenal gland 
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phenotype 37,53. Furthermore, Shh signaling has been shown to induce proliferation in 
other cell types, by increasing transcription of cyclin D1 and D2 genes 54. Analysis of the 
Shh signaling pathway showed that BPA increased mRNA and protein levels of Shh, as 
well as protein levels and activity (determined by nuclear translocation) of Gli1, a key 
transcription factor in the Shh signaling pathway. Additionally, inhibition of the Shh 
pathway by cyclopamine, a well-known Shh signaling pathway antagonist, blocked BPA-
induced increase in proliferation. Collectively, these results suggest that BPA activates 
Shh signaling to increase adrenal cortical cell proliferation. Shh signaling pathway is not 
only important for cell proliferation but is involved in a variety of other developmental 
processes that may be altered due to BPA exposure 54. Previous studies have 
demonstrated altered Shh levels in adrenal tumors in both adult and pediatric patients, 
indicating its involvement in adrenal cancer, and suggesting that BPA may increase the 
risk of adrenal carcinoma tumors 55,56.  
The ability of estrogen to activate Shh signaling has previously been shown in breast and 
gastric cancer cells 57-59. Therefore, I examined the hypothesis that BPA increases adrenal 
cell proliferation through ERb-mediated activation of the Shh pathway. As shown in 
Chapter 4, the ERb-specific antagonist PHTPP blocked the stimulatory effects of BPA on 
PCNA, cyclin D1, and cyclin D2 levels, suggesting that ERb is involved in mediating 
BPA-induced adrenal cell proliferation. Furthermore, PHTPP was also shown to prevent 
the stimulatory effects of BPA on Shh and Gli1 protein levels, linking ERb to the 
activating the Shh signaling pathway following BPA treatment. This is consistent with 
previously reported findings that estrogen activates the Shh signaling pathway through 
ERa 57-59. However, my findings demonstrate for the first time that ERb, through a direct 
or indirect mechanism, regulates the Shh signaling pathway.  
Taken together, these findings suggest that BPA acting through ERb activates the Shh 
signaling pathway and results in increased adrenal cortical cell proliferation (Figure 5.1). 
Changes and dysregulation in cell proliferation have previously been associated with 
increased risk of cancer in numerous tissues 35,54,60. As well, BPA has been shown to be 
associated with various types of cancers in both human and experimental animal studies 
61-63. Therefore, it is tempting to speculate that an increase in adrenal cell proliferation 
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could lead to an increased risk of adrenal cortical cancer. Moreover, higher levels of 
adrenal proliferation in vitro suggest an increased potential for steroid hormone 
production. If these findings could be extrapolated to humans, it is conceivable that 
prenatal BPA exposure could lead to chronically elevated glucocorticoid levels. In 
addition, due to the ubiquitous nature of both Shh and ER expression, there is the 
potential that this novel BPA signaling pathway induced cell proliferation may be 
applicable to other tissues, leading to numerous risks, including an increased risk of 
cancer.  
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Figure 5.1: A schematic representation of the postulated molecular pathway by 
which BPA stimulates adrenal cortical cell proliferation. 
BPA readily crosses the cell membrane into the cytoplasm where it binds to and activates 
ERβ. The activated ERβ translocates to the nucleus where it promotes transcription of the 
shh gene, leading to increased shh mRNA and protein. Shh is secreted, acts in an 
autocrine/paracrine fashion and binds to Ptch1 receptor, preventing Ptch1 from inhibiting 
SMO. SMO is then released from the plasma membrane into the cytoplasm, leading to 
the release of a complex containing the key shh transcription factor Gli1. Gli1 
translocates to the nucleus where it binds to the promoters of key proliferation factors, 
such as CCND1 and CCND2, and enhances their transcription, and ultimately leading 
to increased cell proliferation. 
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5.2 Future Directions 
The findings reported in this thesis reveal an important role of prenatal BPA in altering 
adrenal gland development and steroidogenic function in adult mouse offspring, and 
defines novel mechanisms of BPA actions in stimulating both adrenal StAR expression 
and adrenal cortical cell proliferation. However, it is important to recognize there are 
numerous important questions that need to be addressed, and are discussed below. 
5.2.1 To study the effects of prenatal BPA on the other 
components of the steroidogenic pathway  
The ZG is essential for the production of the steroid hormone aldosterone, which acts on 
the distal tubule and collecting duct of the kidney to promote sodium reabsorption 64-66. 
Aldosterone is synthesized from corticosterone by the enzyme Cyp11B2, localized in the 
ZG, as part of adrenal steroidogenesis (Figure 1.8) 64-66. The regulation of aldosterone 
production is not only controlled by ACTH, but is also regulated by angiotensin II and 
potassium levels 64,65. Moreover, changes in aldosterone levels can result in altered blood 
pressure due to its actions on sodium reabsorption 64,65. Indeed, epidemiological evidence 
suggests an association between high BPA levels in plasma/urine and hypertension 67,68. 
However, there are currently no known studies that have examined the effects of BPA on 
aldosterone or Cyp11B2 levels. Thus, it is of importance to determine the potential 
effects of BPA on aldosterone production and regulation, and to examine the 
physiological consequences these effects may have.  
The adrenal glands are also essential in producing precursors to sex hormones, such as 
DHEA from the ZR 64,66. DHEA is not only required for the synthesis of estrogens and 
testosterone in the adult reproductive system, but is critical for estrogen production by the 
placenta during fetal development 64,66. Previous studies using an adult adrenal gland cell 
line (H295R) have demonstrated that BPA treatment resulted in altered levels of 
progesterone, testosterone, estrone, and estradiol 69.  However, the effects of prenatal 
BPA on DHEA levels in the adrenal glands and the potential mechanism behind these 
effects are largely unknown. Therefore, further investigation into the effects and 
mechanism of BPA’s actions on steroid hormones other than glucocorticoids in the fetal 
and adult adrenal gland, and the long-term consequences of these effects, is warranted.  
 172 
5.2.2 To determine the precise molecular mechanism behind the 
effects of BPA on StAR protein levels  
In Chapter 3, I was not able to completely elucidate the potential molecular mechanism 
underlying the effect of BPA on StAR protein levels. However, I suggest that BPA does 
not affect the gene transcription, translation, or protein half-life of StAR. Thus, further 
research is warranted to examine the effects of BPA on StAR regulation in human 
adrenocortical cells due to its essential role as the rate-limiting step in adrenal 
steroidogenesis 47,70. The mechanisms underlying StAR regulation are not yet fully 
understood, and new mechanisms and pathways are being continually discovered 47,71. As 
such, BPA may affect StAR protein levels through an undiscovered novel mechanism.  
However, there are a few possible mechanisms that may underlie BPA-induced StAR 
protein levels, which include: (1) Changes in the 32-kDa isoform of StAR 72,73, which I was 
unable to detect by western blotting. The role of the 32-kDa isoform of StAR is not fully 
understood, yet it is interesting to speculate that an increase in the mature 30-kDa StAR 
may be complimented by a corresponding decrease in the 32-kDa StAR; (2) alterations in 
transport and/or cleavage of StAR protein at the OMM. It was proposed that a change in 
transport and/or cleavage of StAR would need to be accompanied with a change in StAR 
pre-protein. However, this may not be the case and further investigation to confirm this is 
needed; and (3) changes in multiple steps of the StAR regulation pathway. As such, if 
there are changes in multiple steps of the StAR regulation pathway, smaller changes in 
individual steps may not be sensitive enough to be detected in these experiments. Further 
studies need to examine each of these potential mechanisms.   
5.2.3 To determine whether aspects of the signaling pathway 
identified in vitro can be observed in BPA-exposed mouse 
adrenal glands 
In Chapter 4, I presented a novel molecular pathway by which BPA acts on ERb to 
activate the Shh signaling pathway, which in turn leads to increased cell proliferation in 
H295A cells. However, future studies are necessary to determine whether this same 
molecular pathway operates in vivo in the adrenal glands of both fetal and adult mouse 
offspring following prenatal BPA exposure. These include (1) measuring key 
proliferation markers and factors (PCNA, cyclin D1, and cyclin D2); (2) determining the 
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levels (mRNA and protein) of key Shh signaling pathway factors Shh and Gli1, and their 
activity in vivo (nuclear translocation of Gli1); and (3) examining levels of ERb and its 
activity (nuclear translocation) in adrenal glands of both fetal and adult offspring after 
prenatal BPA exposure. The foregoing experiments will ascertain whether the observed 
mechanism in vitro is also in operation in vivo following prenatal exposure to BPA.  
5.2.4 To determine the adrenal phenotype in ERa and ERb null 
mice  
It has previously been shown that estrogen is essential for adrenal gland development in 
rhesus monkeys 36,42,74. However, there are currently no known studies examining the 
effects on adrenal gland development and/or function in ERa and ERb null mice. 
Additionally, experiments in this thesis have demonstrated an important role of ER in 
regulating adrenal steroidogenesis, as well as adrenal cortical cell proliferation via ERb-
mediated activation of the Shh signaling pathway. Thus, it is of important to characterize 
adrenal gland phenotypes in both fetuses and adults of adrenal-specific ERa and ERb 
knockout mice. These novel in vivo mouse models will define the role of ERa and ERb 
during the development of the adrenal gland in the fetus, and the potential long-term 
function of ERa and ERb in the adult offspring.  
Generation of these mouse models would be useful in the future to further examine the 
effects of BPA on adrenal gland development and function. Specifically, it will help to 
further confirm the role of BPA in regulating adrenal steroidogenesis, and provide 
definitive evidence to either support or refute if these effects are mediated through ERa 
and/or ERb. These genetically modified mouse models will also be valuable in 
confirming the role of ERb in activating the Shh signaling pathway, and consequent 
stimulation of adrenal cortical cell proliferation. Additionally, these mouse models will 
be invaluable in determining the mechanism of actions of other EDCs, acting through 
ER, on adrenal gland development and function.  
 174 
5.2.5 To determine the effects of BPA analogues on adrenal gland 
development and function 
The continued research into the adverse effects of BPA has led to many manufacturers 
discontinuing the use of BPA in their products 75,76. As such, BPA analogues such as 
Bisphenol S, F, and AF (BPS, BPF, and BPAF) are being used increasingly as 
replacement for BPA in products due to their similar chemical properties (Figure 5.2) 
75,76. However, due to the structural similarities, there is potential for these chemicals to 
not only exert the same effects as BPA but to cause other adverse effects. Indeed, recent 
studies have found that exposure to BPS, BPF, and BPAF affect the reproductive 77,78, 
endocrine 77, neurological 79,80, cardiovascular 81, and metabolic 82,83 systems. 
It has previously been demonstrated that treatment of the H295R cell line (adult adrenal 
gland) with increasing concentrations of BPS, BPF, and BPAF resulted in various effects 
on steroidogenic function differing from that of BPA 84. Therefore, future in vitro and in 
vivo studies are needed to further understand the potential adverse effects of these 
bisphenol analogues on adrenal development and function, which will contribute to the 
growing literature concerning the question of whether bisphenol analogues are safer 
alternatives to BPA.  
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Figure 5.2: BPA and its analogues structure 84 
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5.3 Conclusions 
Insults during the critical period of development can often lead to long-term adverse 
effects, resulting in disease and dysfunction in later life 13,14. Exposure to EDCs such as 
BPA during critical periods of organ development is alarming for numerous reasons. 
First, the presence of BPA in the environment is ubiquitous, and is detectable in the urine 
of over 91% of Canadians 85. Second, BPA has been demonstrated to cross the placenta 
and reach fetal circulation during organ development 86,87. Lastly, BPA is known to work 
through several receptors and alter numerous cell signaling pathways that are involved in 
organ development 61,88. While more attention has been placed on restricting/eliminating 
the exposure of infants to BPA, specifically by banning BPA in baby bottles and 
products, this does not prevent exposure of the fetus to BPA through maternal exposure 
89,90. Epidemiological and animal studies have demonstrated the potential for prenatal 
BPA to cause HPA dysfunction 1-6. However, the specific effects of prenatal BPA on the 
adrenal gland development and function in later life remain largely unknown.  
The experiments presented in Chapter 2 demonstrates the effects of environmentally 
relevant doses of prenatal BPA induces adrenal steroidogenesis independent of ACTH 
levels in a sex-specific manner in the mouse model. The next set of experiments, 
described in Chapter 3, present a potential mechanism by which BPA induces StAR 
protein expression, the rate-limiting factor of steroidogenesis, seen in adult female mice 
prenatally exposed to BPA. Lastly, experiments in Chapter 4 provided evidence of BPA 
altering adrenal development by increasing adrenal cell proliferation via ERb-mediated 
activation of the shh signaling pathway in human adrenocortical cells. A schematic of this 
molecular pathway through which BPA induces adrenal cell proliferation is shown in 
Figure 5.1. This model speculates that BPA freely crosses the cell membrane, which then 
binds to and activates ERb, leading to ERb translocation to the nucleus and consequently 
increasing Shh mRNA and protein levels. Shh is then secreted and acts in an 
autocrine/paracrine fashion to bind to Ptch1 receptor, prevent Ptch1 from inhibiting 
SMO. SMO is released from the plasma membrane into the cytoplasm, leading to the 
release of a complex containing Gli1, a key Shh transcription factor. Gli1 translocates to 
the nucleus where it binds to the promoters of key proliferation factors CCND1 and 
CCND2, and enhances their transcription and ultimately leading to increased cell 
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proliferation. This is a postulated model and further experiments are required to confirm 
if this model translates into an in vivo model system. The long-term consequences of 
increased cell proliferation in fetal adrenal glands must also be considered in the 
application of this model.  
Thus, this thesis supports the hypothesis that prenatal BPA exposure disrupts adrenal 
gland development and steroidogenic function in adult offspring. These findings raise 
concerns about the potential for adverse effects of prenatal BPA on adrenal gland 
development and function, adding to the growing epidemiological evidence suggesting 
adverse effects of BPA on the HPA axis and adrenal gland, and which we hope will 
promote the continual banning of BPA in consumer products by regulatory agencies.  
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